Abstract
Ischemic stroke has been a prominent focus of scientific investigation owing to its high prevalence, complex pathogenesis, and difficulties in treatment. Mitochondria play an important role in cellular energy homeostasis and are involved in neuronal death following ischemic stroke. Hence, maintaining mitochondrial function is critical for neuronal survival and neurological improvement in ischemic stroke, and mitochondria are key therapeutic targets in cerebral stroke research. With the benefits of high efficacy, low cost, and high safety, traditional Chinese medicine (TCM) has great advantages in preventing and treating ischemic stroke. Accumulating studies have explored the effect of TCM in preventing and treating ischemic stroke from the perspective of regulating mitochondrial structure and function. In this review, we discuss the molecular mechanisms by which mitochondria are involved in ischemic stroke. Furthermore, we summarized the current advances in TCM in preventing and treating ischemic stroke by modulating mitochondria. We aimed to provide a new perspective and enlightenment for TCM in the prevention and treatment of ischemic stroke by modulating mitochondria.
1 Introduction
Stroke is a devastating disease with high disability and mortality rates worldwide (). Approximately 7,95,000 people suffer from either new or recurrent strokes annually, increasing the economic burden on the family and society (Virani et al., 2020). Most strokes are ischemic, accounting for approximately 87% of all strokes. Ischemic stroke causes brain tissue necrosis due to narrowing or occlusion of the blood supply arteries (carotid and vertebral arteries) and insufficient blood supply to the brain (Shao et al., 2020).
In patients with ischemic stroke, a significant decline in focal cerebral blood flow causes glucose and oxygen deprivation (OGD). Mitochondrial dysfunction is an early and initiating event in OGD following ischemia. It is increasingly evident that it plays a critical role in the onset, development, and pathology of ischemic stroke (Song et al., 2022). During ischemic stroke, OGD causes adenosine triphosphate (ATP) consumption and Na+/K+ ATPase pump failure, resulting in neuronal membrane depolarization and excessive glutamate release. Excessive Ca2+ influx can cause reactive oxygen species (ROS) production and mitochondrial dysfunction, such as an imbalance in mitochondrial dynamics, mitochondrial-induced apoptosis, mitochondrial biogenesis dysfunction, and mitophagy over-activation. These cellular processes eventually lead to neuronal cell death.
The most effective treatment for acute ischemic stroke is reperfusion therapy, which aims to restore blood flow and oxygen levels before neuronal damage occurs. Tissue plasminogen activator (tPA) is the only thrombolytic agent approved by the U.S. Food and Drug Administration for patients with acute ischemic stroke (). However, the narrow treatment window and the risk of complications limit its clinical application (Zhang et al., 2022; Li et al., 2022c). Additionally, tPA can cause mitochondria to produce excessive ROS, exacerbating cell damage (). New therapeutic agents are required to address the paucity of stroke management approaches. Increasing evidence suggests that maintaining mitochondrial function is critical for neuronal survival and neurological improvement in ischemic stroke, and mitochondria are the key therapeutic targets in cerebral stroke research (; Zhou et al., 2021; Zhong et al., 2022). Therefore, a promising treatment option for ischemic stroke that targets mitochondria is needed.
Chinese herbs and acupuncture are essential components of traditional Chinese medicine (TCM). In clinical trials and basic research, Chinese herbs and acupuncture have demonstrated therapeutic effects in preventing and treating ischemic stroke (Zhang et al., 2021; Song et al., 2022). Further studies reported that Chinese herbs and acupuncture could prevent and relieve cerebral ischemia injury in vivo and in vitro and have neuroprotective effects by modulating the mitochondrial respiratory chain (Zhong et al., 2009), increasing mitochondrial biogenesis (Sun et al., 2021), inhibiting the mitochondrial apoptotic pathway () and attenuating excessive mitophagy (Ting et al., 2017). However, only a few studies have comprehensively reviewed these studies hindering the elucidation of the mechanism of action of TCM and the development of clinical applications. Moreover, the existing review, published 2 years ago, only summarized the effects of Chinese herbs on mitochondrial permeability transition pore (mPTP) overopening-induced ischemic neuron apoptosis. Nonetheless, the regulatory effects of TCM on mitochondria in the treatment of ischemic stroke are multifaceted and acupuncture, an integral aspect of TCM, appears to be overlooked in the treatment of ischemic stroke by restoring mitochondrial function.
Understanding the molecular mechanisms of the mitochondria involved in ischemic stroke is crucial to identify potential interventional targets. Thus, we first discuss the role of mitochondria in ischemic stroke. We subsequently summarized the recent advances in TCM in preventing and treating ischemic stroke by regulating mitochondria. We aimed to provide a new perspective and insight into the use of TCM in treating ischemic stroke by improving mitochondrial structure and function.
2 The role of mitochondria in ischemic stroke
2.1 Ischemic stroke cascade involves mitochondrial function and structure changes
2.1.1 Ischemic stroke cascade involves mitochondrial function changes
Mitochondria produce the majority of ATP via the mitochondrial respiratory chain and oxidative phosphorylation to meet the high-energy demands of neurons in the brain that are extremely sensitive to ischemia and hypoxia. Within minutes of the onset of cerebral ischemia, ATP depletion deactivates the Na+/K+ ATPase pump, causing excessive glutamate release into the extracellular fluid (Sarmah et al., 2020). Overactivation of glutamate receptors, such as N-methyl-D-aspartate-receptor, α-amino-3-hydroxy-5-methyl-4-isox-azolepropionic acid receptor, and kainic acid receptor, results in Ca2+ influx and accumulation into cells (Hu et al., 2018; ; ). A large Ca2+ influx leads to a series of events ranging from mPTP opening and dissipation of mitochondrial membrane potential (MMP) to the release of cytochrome c (Cyt-c) or apoptosis-inducing factor (AIF), thus activating effector caspases and eventually causing neuronal death (; Li et al., 2020). Concomitantly, decreased ATP depletes nicotinamide adenine dinucleotide (NAD+), and the reduced NAD+ drives mitochondria to the vicinity of the endoplasmic reticulum to form mitochondria-associated endoplasmic reticulum membranes (MAMs). Moreover, certain MAM-related proteins join mPTP to regulate its opening, an important marker of cerebral cell death during ischemia/reperfusion (I/R).
In addition to energy production, mitochondria are the primary producers of intracellular ROS and are sites of eukaryotic oxidative metabolism. Disrupting mitochondrial electron transport increases ROS generated during cerebral ischemia, particularly during reperfusion (). Further, this excess ROS affects mitochondrial function and promotes neuroinflammation and neuronal apoptosis after oxygen-glucose deprivation/reoxygenation (OGD/R) (Yang et al., 2021).
2.1.2 Ischemic stroke cascade involves mitochondrial structure changes
In addition to the function of mitochondria, their structure also plays an important role in the pathophysiological process of ischemic stroke. Mitochondria are highly dynamic cellular organelles that can change the shape, size, position, and integrity of mitochondrial DNA (mtDNA) through highly coordinated fission, fusion, and transport to tactical locations. The imbalance of mitochondrial fission and fusion after stroke may increase mitochondrial fragmentation, cause aberrant mitochondrial morphology, and disrupt mitochondrial homeostasis, leading to mitochondrial dysfunction and ultimately triggering neuronal death (Li et al., 2022). Additionally, mutation of gene-encoded subunits in mtDNA results in increased ROS generation, which makes mtDNA more susceptible to mutations than nuclear DNA (Zhang et al., 2022). Researchers have reported that the frequency of mtDNA mutations was significantly higher in the brains of patients with ischemic stroke (Luan et al., 2021). In summary, the ischemic stroke cascade involves changes in mitochondrial function and structure, indicating that mitochondrial structure and function play a critical role in the pathogenesis of ischemic stroke.
2.2 Mitochondrial biogenesis in ischemic stroke
Mitochondrial biogenesis is a multifaceted process involving the coordinated regulation of mitochondrial and nuclear transcription factors. Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) is a major regulator of mitochondrial biogenesis. During ischemic stroke, PGC-1α is first activated by upstream AMP-activated protein kinase (AMPK) phosphorylation and sirtuin 1 (SIRT1) acetylation (Kaarniranta et al., 2018), which then interacts with downstream nuclear respiratory factor 1/2 (NRF1/2), taking part in the expression of nuclear and mitochondrial respiratory factors. The binding of NRF1 to the promoter of the mitochondrial transcription factor A (TFAM) gene is enhanced under oxidative stress. Activated TFAM promotes mtDNA copying, transcription, and related protein synthesis, ultimately inducing mitochondrial biogenesis (Ryoo and Kwak, 2018). Additionally, two mitochondrial proteins, uncoupling protein 2 and superoxide dismutase 2, both regulated by PGC1-α, play a pivotal role in counteracting the damaging effects elicited by excessive oxidative stress in ischemic stroke (). Peroxisome proliferator-activated receptor gamma agonists can upregulate PGC-1α, NRF1, TFAM, and cytochrome c oxidase subunits I and IV and enhance mitochondrial biogenesis in ischemic stroke (Yang et al., 2018). This indicated that mitochondrial biogenesis exerted a protective effect by enhancing the signal transduction pathways upstream of mitochondrial biogenesis.
Generally, mitochondrial biogenesis plays an important role as an endogenous protective mechanism in ischemic stroke. Therefore, boosting the signal transduction pathways upstream of mitochondrial biogenesis, such as the PGC-1α signaling cascade, may become a novel therapeutic strategy against ischemic brain damage.
2.3 Mitochondrial dynamics in ischemic stroke
Mitochondrial dynamics include fission and fusion. Mitochondrial fission allows damaged mitochondria to separate, leading to their subsequent elimination by mitophagy. The production of one or more daughter mitochondria is highly dependent on dynamin-related protein 1 (Drp1). Mitochondrial fusion facilitates the complementation of neighboring mitochondria, enabling the survival of damaged mitochondria (Zhou et al., 2021). It is a two-step process that requires the fusion of outer and inner mitochondrial membranes, mediated by mitofusins-1/mitofusins-2 (Mfn1/2) and optic atrophy 1 (Opa1), respectively.
The interaction between calcium overload, ROS production, and mPTP increases mitochondrial fission and decreases mitochondrial fusion in ischemic stroke (Zhou et al., 2021). Although increased mitochondrial fission during hypoxia may increase mitochondrial energy production, which is beneficial for maintaining neural function after stroke (Quintana et al., 2019), inducing excessive mitochondrial fission is harmful to neurons (Zhang et al., 2020). Excessive mitochondrial fission affects intracellular calcium homeostasis, exacerbates excitotoxicity, and accelerates neuronal death after ischemic stroke (Zhou et al., 2021). Researchers have observed increased levels of Drp1 in mice subjected to cerebral ischemia and reperfusion injury. After the knockdown of Drp1, oxidative stress, mitochondrial ROS production, and infarct volume decrease, contributing to the survival of neurons in cerebral ischemia (). Mitochondrial fusion can repair damaged mitochondria and produce additional energy by upregulating the activity of ATP synthase through mitochondrial cristae remodeling (). The levels of mitochondrial fusion proteins, such as Mfn-1/Mfn-2 and Opa1, decrease after cerebral ischemia (Rutkai et al., 2019). However, hypoxia-induced apoptosis improved when Mfn-2 was restored (Zhou et al., 2022).
In summary, inhibiting excessive mitochondrial fission, promoting mitochondrial fusion, and restoring the balance of mitochondrial dynamics are beneficial for ischemic stroke recovery. Maintaining this balance can serve as a target for treating ischemic stroke.
2.4 Mitophagy in ischemic stroke
Mitophagy is a type of selective autophagy in which damaged or dysfunctional mitochondria are removed. In ischemic stroke, mitophagy could be predominantly mediated by the PINK1/Parkin pathway, Bcl-2/E1B-19 KD-interacting protein 3 (BNIP3), NIP3-like protein X (NIX, also known as BNIP3L), and FUN14 domain containing 1 (FUNDC1). Shen et al. demonstrated that mitophagy could protect brain cells from ischemic injury during the ischemic phase of stroke (Shen et al., 2021). In contrast, mitophagy serves as a double-edged sword when the brain suffers from reperfusion injury. Activating mitophagy to clear excessively aggregated and damaged mitochondria reduces neuronal damage caused by cerebral I/R injury (Li et al., 2018; Wang and Xu, 2020; Wu et al., 2021). However, some studies have shown that inhibiting excessive mitophagy can protect against cerebral I/R injury in middle cerebral artery occlusion (MCAO) rats (Lan et al., 2018; Jakic et al., 2019). Inhibition of excessive mitophagy could exert neuroprotective effects against neuronal death caused by chronic cerebral hypoperfusion (Su et al., 2018).
Mitophagy is important for the pathogenesis of cerebral I/R damage. Regulation of mitophagy could exert neuroprotective effects in ischemic stroke, although some issues regarding its role in ischemic stroke remain unclear. It would be meaningful to explore the role of mitophagy in treating I/R.
2.5 Proteins associated with mitochondria-dependent apoptosis in ischemic stroke
Apoptosis is a planned or controlled cell death triggered by mitochondrial malfunction through intrinsic and extrinsic pathways. Mitochondria are associated with many apoptosis-related proteins, suggesting that they are crucial for cell death following I/R (Yang et al., 2018). Many studies have revealed that B cell lymphoma (BCL-2) family proteins regulate neuronal death in cerebral ischemic stroke (). After I/R, apoptotic members of the Bcl-2 protein family (e.g., Bax and Bak) are inserted into the outer mitochondrial membranes, and MMP is significantly downregulated. Another decisive step in the apoptotic cascade is related to the mPTP. Transient opening of the mPTP in the mitochondrial inner membrane after I/R causes MMP collapse. Several apoptosis-related proteins (e.g., AIF, Cyt-c, endonuclease G [Endo G], the second mitochondrion-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI [Smac/Diablo]) originating in the mitochondria are released into the cytoplasmic matrix (Zhou et al., 2021). After migration to the cytoplasmic matrix, Cyt-c interacts with apoptosis-activating factor-1 (Apaf-1), deoxyadenosine triphosphate (dATP), and procaspase-9 to form the apoptosome, which then activates procaspase-9 and follows with caspase-9 to cleave and activates caspase-3 (Wang et al., 2020). Smac binds to and inhibits inhibitor-of-apoptosis proteins (IAPs), which normally inhibit procaspase activation and caspases activity (Zhao et al., 2020). AIF can trigger caspase-independent chromatin condensation and large-scale DNA breakage (Yang et al., 2017) and functions as a mitochondrial effector of apoptotic cell death following translocation from mitochondria to the nucleus ().
Overall, modulating the expression of apoptotic members of the Bcl-2 protein family and preventing translocation of AIF, Cyt-c, and Smac from the mitochondria into the cytoplasmic matrix can serve as targets for the treatment of ischemic stroke.
3 Progress in ischemic stroke prevention and treatment using TCM that regulates mitochondria
Based on the above summary, we identified several targets for treating ischemic stroke from the mitochondrial perspective. In clinical and experimental studies, TCM has demonstrated significant efficacy in preventing and treating ischemic stroke. The mechanisms of action of TCM have also been gradually revealed in recent years. Many studies have revealed that TCM exerts therapeutic effects on ischemic stroke by regulating the mitochondria. Therefore, we summarized the literature on acupuncture, herbal extracts, effective TCM compounds, and TCM prescriptions in preventing and treating ischemic stroke and attempted to further clarify the molecular mechanisms of TCM in improving ischemic stroke from the perspective of regulating mitochondria.
3.1 Acupuncture and its molecular mechanisms for regulating mitochondria in ischemic stroke
3.1.1 Acupuncture pretreatment for regulating mitochondria in ischemic stroke
The MCAO group exhibited apparent mitochondrial structural abnormalities, including a reduction in mitochondrial volume and number, swelling, vacuolization, formation of autophagosomes and lysosomes, and broken/irregular/disappeared inner membranes and cristae. However, 5–7 consecutive days of electroacupuncture (EA) pretreatment reduced mitochondrial abnormalities, including an increase in mitochondrial volume and number (Sun et al., 2021), less swelling (Tian et al., 2022), a relatively integrated membrane and cristae (Zhang et al., 2018), and a reduction in the number of autolysosomes (Tian et al., 2022). Elevated radical generation (Sun et al., 2021), attenuated MMP levels (Mao et al., 2020; Sun et al., 2021; Tian et al., 2022), and reduced citrate synthase (Sun et al., 2021) were detected in the MCAO group 24 h after reperfusion, compared with those in the control group. These trends could be reversed by EA pretreatment. Additionally, researchers reported that five consecutive days of EA pretreatment at the Baihui (DU20) acupoint induced neuronal protection by inhibiting the expression (Zhang et al., 2017; Zhang et al., 2018) and translocation (Zhang et al., 2018) of mitochondrial Drp1 in rats with focal cerebral IR injury. Meanwhile, EA pretreatment at the DU20 and Shuigou (DU26) acupoints for 5 days was applied to treat cerebral I/R injury in rats and exerted neuroprotective effects by inhibiting the autophagy-related p-ULK1/FUNDC1 pathway (Mao et al., 2020; Tian et al., 2022). EA pretreatment at the DU20 acupoint induced cerebral ischemic tolerance, increased the expression of NRF-1, TFAM, and mtDNA levels, and further promoted mitochondrial biogenesis by activating CB1R-dependent PGC-1α (Sun et al., 2021). Sun et al. found that the release of Cyt-c in the cytoplasm (Cyto-Cyt-c) was reduced in the EA group 24 h after reperfusion compared with that in the I/R mice group induced by MCAO (Sun et al., 2021). Their findings were consistent with another previous study that also found a significant decrease in Cyto-Cyt-c levels in the EA group compared with the IR group at 6, 24, and 48 h after reperfusion (Zhang et al., 2018).
In summary, EA pretreatment promoted mitochondrial biogenesis 4 h after reperfusion. At 6, 24, and 48 h after reperfusion, EA pretreatment inhibited mitochondrial fission and apoptosis by decreasing mitochondrial Drp1 and Cyto-Cyt-c levels, respectively. Moreover, after 24 h of reperfusion, EA pretreatment reversed mitochondrial structural abnormalities, inhibited the autophagy-related p-ULK1/FUNDC1 pathway, attenuated radical generation, elevated MMP levels, and increased mitochondrial energy metabolism. Specific mechanisms are shown in Table 1; Figure 1A.
TABLE 1
| Acupuncture method | Animals | Gender | Weight | Animal model | Prevention/treatment | Time period | Insertion depth, Stimulator parameters | Acupoints | Mechanisms | References |
|---|---|---|---|---|---|---|---|---|---|---|
| EA | SD rat | Male | 200–250 g | MCAO (2 h)/R (24 h) | Pretreatment | Pretreatment for 5 days, q.d. 30 min per day | Baihui (DU20):2 mm,Shuigou (DU26):1 mm; alternating frequency of 2/50 Hz; A slight rat limb tremor reflects an appropriate stimulus intensity. | Baihui (DU20) and Shuigou (DU26) | MMP↑,LC3-II/LC3-I↓,p-ULK1↓,FUNDC1↓, mTOR signaling↑ | Tian et al. (2022) |
| EA | SD rat | Male | 220–250 g | MCAO (2 h)/R (24 h) | Pretreatment | Pretreatment for 5 days, q.d. 30min per day | Baihui (DU20):1 mm; Shuigou (DU26):1 mm; density-sparse wave; intensity of 1 mA | Baihui (DU20) and Shuigou (DU26) | MMP↑, FUNDC1↓, LC3-II/I↓, p-mTORC1/mTORC2↑,p62↓ | Mao et al. (2020) |
| EA | SD rat | Male | 300 ± 20 g | MCAO (2 h)/R (6,24,48 h) | Pretreatment | Pretreatment for 5 days, q.d. 30 min per day | Baihui (DU20): 2mm; frequency, 2/15 Hz; intensity of 1 mA | Baihui (DU20) | TUNEL-positive neurons↓, total Drp1↓, Mito-Drp1↓, total-cyt-c↓, cyto-cyt-c ↓ | Zhang et al. (2018a) |
| EA | C57BL6j mice | Male | 25–30 g | MCAO (1 h)/R (4 h,24 h) | Pretreatment | 30 min | frequency of 2/15 Hz, intensity of 1 mA | Baihui (DU20) | cyto-cyt c↓,COXⅣ↑, | Sun et al. (2021) |
| ROS↓,MMP↑, citrate synthase↑,NRF-1↑, | ||||||||||
| TFAM↑,mtDNA↑,PGC-1α↑,TUNEL-positive neurons↓ | ||||||||||
| EA | Wistar rat | Male | 250–300 g | MCAO (2 h)/R (6,24,48 h) | Pretreatment | Pretreatment for 5 days, q.d. 30 min per day | frequency of 2/15 Hz, | Baihui (DU20) | Drp1↓,TUNEL-positive neurons↓ | Zhang et al. (2017b) |
| intensity of 1 mA | ||||||||||
| EA | SD rat | Male | 300–350 g | MCAO (30 min)/R (7 days) | treatment | 7 days, q.d. 25 min per day | Baihui (GV20) 4 mm; Fengfu (GV16):7.5 mm; 150-μs pulse width; intensity of 2.7–3.0 mA | Baihui (GV20) and Fengfu (GV16) | cytosolic p-p38 MAPK/p38 MAPK ↑, Cytosolic GFAP↓, cytosolic p-CREB/CREB↑, Cytosolic Bcl-2↑, Cytosolic Bax↓, Cytosolic Bcl-xL↑, cytosolic Bcl-2/Bax↑, Bcl-xL/Bax↑Mitochondrial Bcl-2↑,Mitochondrial Bax ↓, mitochondrial Bcl-xL ↑,mitochondrial Bcl-2/Bax↑, mitochondrial Bcl-xL/Bax ↑,Mitochondrial and cytosolic Smac/DIABLO↓,Cytosolic XIAP↑, Cytosolic cleaved caspase-3↓ | |
| EA | SD rat | Male | 150–180 g | MCAO (90 min)/R (3 days) | treatment | 30 min/time,2 times per day, lasting for 3 days | Baihui (DU20):3 mm; Qihai (RN6):3 mm; 2 Hz; intensity of 1 mA | Baihui (DU20) and Qihai (RN6) | Bcl-2↑,Bcl-xL↑,cIAP-1↑, cIAP-2↑,caspase-3↓, | Kim et al. (2013) |
| caspase-9↓,caspase-8↓, | ||||||||||
| TUNEL-positive cells ↓, Cleaved PLCγ1↓, Dr5↓ | ||||||||||
| EA | SD rat | Not mentioned | 200–250 g | 4-VO(3 h)/R (48 h) | treatment | 5 times within 48 h, 20min/time | Baihui (DU20):2 mm; Mingmen (DU4):5–7 mm | Baihui (DU20),Mingmen (DU4),Zusanli (ST36) | mTOR↓,Beclin1↑,LC3↑,IL-6↓, TNF-α↓,IL-1β↓, MDA ↓,SOD↑ | Ting et al. (2017) |
| Zusanli (ST36):7mm; frequency of 40–50 Hz; A slight rat limb tremor reflects an appropriate stimulus intensity. | ||||||||||
| EA | SD rat | Male | 280–300 g | MCAO/R (24 h) | treatment | EA at 5 min and 6 h after reperfusion, 30min/time | frequency of 4/20 Hz; intensity of 1 mA. | Baihui (DU20) and Shenting (DU24) | Cleaved Caspase-3↓, | |
| TUNEL-positive cells↓, | ||||||||||
| Cofilin Rod↓, MAP2 degradation↓, cofilin in mitochondria and cytoplasm↓ | ||||||||||
| EA | SD rat | Male | 200–220 g | MCAO (90min)/R (24 h) | treatment | 30 min EA treatment | Renzhong (DU26):1 mm | Baihui (DU20) and Renzhong (DU26) | RCR↑, succinic dehydrogenase↑, NADH dehydrogenase↑, cytochrome C oxidase↑ | Zhong et al. (2009) |
| Baihui (DU20):4 mm; disperse-dense waves of 5/20 Hz (28.5 ms/15 ms pulse duration) of frequency; current density of 2–4 mA | ||||||||||
| EA | SD rat | Male | 220–250 g | MCAO (2 h)/R (24 h) | treatment | 2 times within 24 h | Not mentioned | Not mentioned | MMP↑,ATP↑,Opa1↑,Mfn1↑, COX IV↓,VDAC↓, | Wang et al. (2019a) |
| TOMM20↓,NOX↓,ROS↓,MDA↓,SOD↑,iNOS↓,3-NT↓,Drp1↑,Parkin↑, Mfn2↑,translocation of Parkin and LC3 from the cytoplasm to mitochondria↑ | ||||||||||
| EA | SD rat | Male | 200–230 g | MCAO (15 min)/R (24 h) | treatment | 2 times within 24 h, | frequency of 30–50 Hz; different electric current | Baihui (GV20), Mingmen < | LDH↑, SDH↑,Na + -K+ | Tian et al. (2015) |
| 30min/time | intensities: 5 mA, 3 mA and 1 mA. | (GV4) and Zusanli (ST36). | ATPase↑ | |||||||
| EA | SD rat | Male | 280 ± 20 g | MCAO/R (7 days) | treatment | 7 days, q.d. 30min per day | Continuous wave of 2/100 Hz and 2–4 V | Baihui (GV20), Shuigou | MDA↓,iron↓,SOD↑,GSH↑,GPX4↑,FTH1↑,Tf↓,TfR↓ | Li et al. (2021a) |
| (GV26), Sanyinjiao (SP6), and Neiguan (PC6). | ||||||||||
| EA | SD rat | Male | 300 ± 20 g | MCAO (90 min)/R (7 days) | treatment | 7days, q.d. 20min per day | Baihui (DU20)and Shenting (DU24):0.2 cm; disperse-dense waves of 4/20 Hz; current density of 0.5 mA | Baihui (DU20),Shenting (DU24) | LC3-Ⅱ/LC3 Ⅰ↑,BNIP3L↑, | Zhong et al. (2022b) |
| SQSTM1↑, TUNEL positive cells↓ |
The molecular mechanism of acupuncture in the treatment of ischemic stroke by targeting mitochondria.
Notes: ↑, upregulate; ↓, downregulate; SD, Sprague-Dawley; MCAO/R, middle cerebral artery occlusion/reperfusion; q. d., once a day; ULK1, Unc-51-like kinase 1; LC3-I/Ⅱ, Light chain 3I/Ⅱ; LC3B-II, light chain 3B II; p62, Sequestosome-1; p38 MAPK, p38 mitogen-activated protein kinases; CREB, cAMP, response element binding protein; PLC γ, 1, phospholipase C γ 1; Dr5, death receptor 5; MAP2, microtubule-associated protein-2; NADH, nicotinamide adenine dineucleotide; RCR, respiratory control ratio; iNOS, inducible nitric oxide synthase; LDH, lactate dehydrogenase; SDH, succinate dehydrogenase; GSH, glutathione; SQSTM1, Sequestosome-1; VDAC, voltage-dependent anion channel; Tomm20, translocase of outer mitochondrial membrane 20 homolog; NOX, oxidase; 3-NT, 3-nitrotyrosine; GPX4, glutathione peroxidase 4; Tf, transferrin; TfR1, transferrin receptor 1, FTH1, ferritin heavy chain 1; GFAP, glial fibrillary acidic protein; mito-Drp1, mitochondrial dynamin-related protein 1; COX IV, cytochrome c oxidase IV; IL-6, interleukin 6; IL-1β, interleukin 1β; TNF-α, Tumor necrosis factor-alpha; p-mTORC1, phosphorylated mTORC1; 4-VO/R, 4-vessel occlusion/reperfusion.
FIGURE 1
3.1.2 The effect of acupuncture after ischemic stroke in regulating mitochondria
In the MCAO group, the neuronal mitochondria became swollen, the mitochondrial cristae and outer membrane were broken, and EA alleviated the mitochondrial structure abnormalities within 24 h after reperfusion (Li et al., 2021). Acupuncture can alleviate cerebral I/R injury by increasing MMP levels and inhibiting nitro/oxidative stress by downregulating oxidase, ROS, and malondialdehyde (MDA) levels and upregulating superoxide dismutase (SOD) (Ting et al., 2017; Wang et al., 2019). In addition, EA at DU20 and DU26 for 30 min decreased the neurological deficit score, improved the respiratory control ratio, and promoted the activities of respiratory enzymes, including succinic dehydrogenase, NADH dehydrogenase, and cytochrome C oxidase, in MCAO rats (Zhong et al., 2009). These findings are consistent with those reported by Tian et al. (Tian et al., 2015). Tian et al. further pointed out that 3 mA EA could more effectively elevate the activities of succinic dehydrogenase and lactate dehydrogenase compared to 1 mA EA and 5 mA EA in the brain tissue of rats with I/R injury (Tian et al., 2015). Zuo et al. noticed that EA at ZuSanLi (ST36), DU20, and Mingmen (DU4) five times within 48 h after reperfusion could improve cerebral I/R by inhibiting excessive autophagy in neurons (Ting et al., 2017). However, Zhong et al. conducted 7 days of EA treatment at DU20 and Shenting (DU24) after reperfusion and reported that EA could alleviate cerebral I/R injury and improve neural function by promoting BNIP3L mediated autophagic clearance (Zhong et al., 2022). Another study also demonstrated that EA within 24 h after reperfusion decreased the accumulation of damaged mitochondria by increasing Pink1/Parkin-mediated mitophagy clearance to protect cells against neuronal injury in cerebral I/R (Wang et al., 2019). Furthermore, within 24 h after reperfusion, EA at DU20 and Fengfu (DU16) increased the expression of anti-apoptotic Bcl-2, Bcl-Xl, and cellular inhibitor of apoptosis- 1,-2 (cIAP-1, -2), and decreased the activities of caspase-3, -8, and -9 compared with the untreated rats with MCAO (Kim et al., 2013). Similarly, EA at DU20 and DU16 for 7 consecutive days activated p38 MAPK-mediated anti-apoptotic signaling pathways, which ultimately contributed to the prevention of Smac/DIABLO translocation and subsequent restoration of the X-linked inhibitor of apoptosis protein (XIAP) suppression of caspase-3 in the cortical peri-infarct area (). Another study also found that EA treatment within 6 h of ischemic stroke could attenuate ischemic brain injury and cellular apoptosis by inhibiting mitochondrial translocation of cofilin and caspase-3 cleavage () (Figure 1B).
In summary, acupuncture treatment and pretreatment could both restore mitochondrial morphology, improve MMP levels, further upregulate mitochondrial energy metabolism, attenuate mitochondrial autophagy, and inhibit mitochondrial-dependent apoptosis. Acupuncture pretreatment promoted mitochondrial biogenesis and inhibited mitochondrial fission. Additionally, acupuncture treatment inhibited oxidative stress, cofilin translocation, and activated mitochondrial autophagy. The detailed mechanisms are shown in Table 1 and Figures 1A,B.
3.2 Herbal extract and its molecular mechanisms by regulating mitochondria in treating ischemic stroke
3.2.1 Herbal extract pretreatment in regulating mitochondria of ischemic stroke
Although the clinical treatment of ischemic stroke with a single herb is rare, in recent years, researchers have reported that the individual application of certain herbs has the potential to treat diseases. Mitochondrial ultrastructure injury was partially improved in cerebral I/R rats after pretreatment with in vitro cultured Bos taurus domesticus Gmelin or Chrysanthemum morifolium Ramat. extracts (Lin et al., 2010; Lu et al., 2020). Pretreatment with herbal extracts (e.g., Astragalus membranaceus (Fisch.) Bge. combined with Panax notoginseng (Burk.) F.H.Chen, Astragalus membranaceus (Fisch.) Bge., and Gardenia jasminoides (Ellis) alleviated nerve injury after cerebral I/R by improving mitochondrial respiration function and energy metabolism (Huang et al., 2012; Huang et al., 2017; Wang et al., 2021). Previous studies have noted that herbal extracts (including Pinellia ternata (Thunb.) Breit., Rosa laevigata Michx., Curcuma Longa L., C. morifolium Ramat., and Lavandula angustifolia Mill.) could play a neuroprotective role in the pretreatment of animal models of MCAO by increasing MMP levels and inhibiting mitochondrial oxidative stress (by upregulating SOD, glutathione, glutathione peroxidase catalase, and downregulating MDA, NO, ROS, and peroxynitrite) (; Lin et al., 2010; Wang et al., 2012; Zhang et al., 2013; Ye et al., 2016). Recent in vitro studies have also shown that Scrophularia ningpoensis Hemsl., Aglaia odorata Lour., Spatholobus suberectus Dunn, and Arctium lappa L. roots exert neuroprotective effects by increasing MMP levels and inhibiting mitochondrial oxidative stress in preconditioned OGD/R cell models (Meng et al., 2018; Park et al., 2018; Wang K. et al., 2020; Yang et al., 2021). Lycium barbarum L. polysaccharide pretreatment decreased cerebral I/R injury in MCAO rats by maintaining mitochondrial fission and fusion balance (upregulating Opa1 and downregulating Drp1) (Liu et al., 2017). Similarly, Arctium lappa L. roots ameliorated OGD/R-induced injury by suppressing AMPK/mammalian target of rapamycin (mTOR)-mediated autophagy (Yang et al., 2021). Herbal extracts (such as P. ternata (Thunb.) Breit., R. laevigata Michx, Curcuma Longa L., S. ningpoensis Hemsl., L. barbarum L. polysaccharides, Astragalus membranaceus (Fisch.) Bge., in vitro cultured B. taurus domesticus Gmelin and Angelica sinensis (Oliv.) (Diels) prevented cerebral I/R injury in MCAO animal models by inhibiting the mitochondria-dependent apoptosis pathway. These herbal extracts upregulated the expression of Bcl-2, mitochondrial Cyt-C (Mito-Cyt-c), cytosolic phospho-Bad (p-Bad)/Bad ratios, and mitochondrial p-Bad/Bad. Additionally, they downregulated the expression of Bax, p53, Apaf1, Bax, Bid, Cyt-c, cleaved PARP-1, and active caspase-3, -9, and -8 (; Huang et al., 2012; Zhang et al., 2013; Wang et al., 2014; Ye et al., 2016; ; Meng et al., 2018; Lu et al., 2020). Evidence from in vitro experiments has demonstrated that A. odorata Lour. and Arctium lappa L. roots showed a significant protective effect in OGD/R cell models by inhibiting the mitochondria-dependent apoptotic pathway (Wang et al., 2020; Yang et al., 2021).
In brief, evidence from in vivo and in vitro studies indicated that herbal extract pretreatment could ameliorate cerebral ischemia by improving mitochondrial ultrastructure, increasing MMP levels, mitochondrial respiration function, and energy metabolism, maintaining mitochondrial dynamic balance, inhibiting mitochondria-related oxidative stress, autophagy, and mitochondria-dependent apoptosis (Figure 2).
FIGURE 2
3.2.2 The effect of herbal extract after ischemic stroke in regulating mitochondria
Not only herbal extract pretreatment can alleviate mitochondrial structural abnormalities, but also herbal extract treatment can mitigate these abnormalities. Seven days of Dengzhanxixin injection treatment can improve decreased and unclear mitochondrial cristae observed in the MCAO rat model () while Ganoderma lucidum (Leyss.ex Fr.) Karst. polysaccharides can alleviate swollen and vacuolized mitochondria observed in OGD/R primary cortical neuronal cells (Zhou et al., 2010). Cordyceps sinensis (BerK.) Sacc. extract improved ATP levels and mitochondrial complexes I-IV in MCAO rats. Cordyceps sinensis (BerK.) Sacc., Curcuma Longa L., and polysaccharides from A. sinensis (Oliv.) Diels decreased oxygen free radicals, NO, ROS, peroxynitrite, glutathione peroxidase, SOD, and Ca2+ and increased MMP and MDA levels in MCAO rats (; Lei et al., 2014; ). These findings are consistent with in vitro studies of C. sinensis (BerK.) Sacc. extract, L. barbarum L. polysaccharides, and polysaccharides from A. sinensis (Oliv.) Diels in alleviating OGD/R injury (Lei et al., 2014; Shi et al., 2017; Zhao et al., 2017; ). Additionally, combining Panax ginseng C.A. Mey. and A. sinensis (Oliv.) Diels partially attenuated cerebral injury by ameliorating Drp1-mediated mitochondrial fission (downregulating Drp1) in vivo and in vitro (Hu et al., 2020). However, Ginkgo biloba L. extract upregulated Drp1 and Opa1 in vivo (Li et al., 2019). Researchers found that G. biloba L. extract induced autophagy by activating the AMPK/mTOR pathway (Li et al., 2019). Both in vivo and in vitro experiments, including C. sinensis (BerK.) Sacc., Curcuma Longa L., L. barbarum L. polysaccharides, G. lucidum (Leyss.ex Fr.) Karst. polysaccharides, and extract of G. biloba L., exhibited obvious neuroprotective effects in MCAO rats, and the OGD/R cell model by inhibiting mitochondrial-dependent apoptosis (; Zhou et al., 2010; Shi et al., 2017; Zhao et al., 2017; Li et al., 2019; ) (Figure 2).
Overall, herbal extract pretreatment and treatment could alleviate abnormal mitochondrial structure; improve MMP, mitochondrial energy metabolism, mitochondrial respiration function, and mitochondrial fusion; and inhibit oxidative stress, mitochondrial fission, and mitochondrial-dependent apoptosis. Furthermore, herbal extract pretreatment suppressed AMPK/mTOR-mediated mitophagy, whereas herbal extract treatment induced autophagy by activating the AMPK/mTOR pathway and promoting mitochondrial fission. Specific mechanisms are shown in Table 2; Figure 3.
TABLE 2
| Herbal extracts | Cell lines and cell models | Animals | Gender | Weight | Animal model | Routes | Dose | Prevention/treatment | Time periods | Mechanisms | References |
|---|---|---|---|---|---|---|---|---|---|---|---|
| In vitro cultured Bos taurus domesticus Gmelin extract | - | SD rat | Male | 240–280 g | MCAO (90 min)/R (24 h) | intragastric administration | 25,50,100 mg/kg | Prevention | Pretreatment for 3 days, q.d.1 h before MCAO and 6 h after MCAO | Bax↓,caspase-9↓,caspase-3↓, Cyto-Cyt-c↓, | Lu et al. (2020) |
| Bcl-2↑,Mito-Cyt-c↑ | |||||||||||
| Chrysanthemum morifolium Ramat. extract | - | SD rat | Male | 250–300 g | MCAO (90 min)/R (22 h) | intraperitoneal injection | 50,100,200 mg/kg | Prevention | 90 min before MCAO | SOD↑, MDA↓, ROS↓ | Lin et al. (2010) |
| Extract of Gardenia jasminoides Ellis, stir-baked until brown, and fried until carbonized | - | SD rat | Male | 250–270 g | MCAO/R (12 h) | intragastric administration | Gardenia jasminoides Ellis (0.5.1 g kg−1), Gardenia jasminoides Ellis stir-baked until brown (0.5.1 g kg−1), Gardenia jasminoides Ellis fried until carbonized (0.5.1 g kg−1) | Prevention | 15 min before MCAO | Na+-K+-ATPase↑,Ca2+-Mg2+-ATPase↑,ROS↓ | Wang et al. (2021b) |
| Astragalus membranaceus (Fisch.) Bge. extract | - | C57BL/6N mice | Male | 18–22 g | CCA(20 min)/R (1/24/48 h) | intragastric administration | 110 mg/kg | Prevention | at 08:00 (10 mL/kg), 4 days, q.d. before CCA, After suturing the skin, the mice continued to be medicated until awakening from anesthesia. | ATP↑, ADP↑,EC↑, | Huang et al. (2012) |
| Na+-K+ATPase↑, p-JNK1/2↓, Cyt-c↓, caspase-9↓, caspase-3↓ | |||||||||||
| Extract of Astragalus membranaceus (Fisch.) Bge. and Panax notoginseng (Burk.) F.H.Chen | - | C57BL/6N mice | Male | 18–22 g | CCA(20 min)/R (1/24 h) | intragastric administration | astragalus extract: 110 mg/kg; total panax | Prevention | at 08:00 (10 mL/kg), 4 days, q.d. before CCA, After suturing the skin, the mice continued to be medicated until awakening from anesthesia. | ATP↑,ADP↑, Na+-K+ATPase↑,p-JNK1/2↓, Cyt-c↓, Caspase-9↓, Caspase-3↓ | Huang et al. (2017) |
| notoginseng saponins:115 mg/kg | |||||||||||
| Lycium barbarum L. polysaccharides | - | SD rat | - | 200–220 g | CCA(30 min)/R (24/72 h) | intraperitoneal injection | 25 mg/kg | Prevention | 3 weeks after the induction of diabetes and continued for 4 weeks before MCAO | Opa1↑, Drp1↓ | Liu et al. (2017) |
| Extract from Pinellia ternata (Thunb.) Breit. | - | SD rat | Male | 250–300 g | MCAO (2 h)/R (24 h) | take orally | 5,10,20 mg/kg | Prevention | Pretreatment for 7 days, q.d. | Bcl-2↑, Bax↓, SOD↑, MDA↓ | Ye et al. (2016) |
| Rosa laevigata Michx. extract | - | SD rat | Male | 250–300 g | MCAO (2 h)/R (24 h) | intragastric administration | 50, 100, 200 mg/kg | Prevention | Pretreatment for 7 days, q.d. | SOD↑,GSH↑, T-NOS↓, NO↓, iNOS↓,p53↓, Apaf1↓,Bcl-2↑, Fas↓, FasL↓,Bax↓,Bid↓, Caspase-8↓, Caspase-9↓, Caspase-3↓, Cyt-c↓, MMP-9↓, COX-2↓ | Zhang et al. (2013) |
| Lavandula angustifolia Mill. extract | - | Kunming mice | Male | 30–34 g | MCAO (2 h)/R (22 h) | intragastric administration | 200,100,50 mg/kg | Prevention | Pretreatment for 3 days, q.d.,2 h after MCAO | MDA↓, SOD↑, CAT↑, GSH-Px↑, GSH/GSSG↑, ROS↓ | Wang et al. (2012) |
| Extract of Arctium lappa L. roots | SH-SY5Y cells; OGD(4 h)/R (24 h) | - | - | - | - | treated with Arctium lappa L. | - | Prevention | 12 h before OGD/R | ROS↓, MMP↑, Bax↓,Cyt-c↓,caspase-3↓, Bcl-2↑,Beclin-1↓, LC3-II↓,SQSTM1/p62↑ | Yang et al. (2021) |
| Extract of Scrophularia ningpoensis Hemsl. | PC12 cells; OGD(2 h)/R (24 h) | - | - | - | - | treated with Scrophularia ningpoensis Hemsl. | 12.5 μg/mL | Prevention | Pretreatment for 8/16 h | SOD↑,GSH-Px↑, CAT↑,LDH↓, MMP↑ | Meng et al. (2018) |
| Aglaia odorata Lour. extract | PC12 cells; OGD(4 h)/R (24 h) | - | - | - | - | treated with Aglaia odorata Lour. extract | - | Prevention | - | ROS↓, cleaved caspase-9/3↓,p53↓, p53/Puma↓, Bcl-2↑ | Wang et al. (2020b) |
| Spatholobus suberectus Dunn extract | SH-SY5Y cells; OGD/R | - | - | - | - | treated with Spatholobus suberectus Dunn extract | 25 or 50 μg/ml | Prevention | Pretreatment for 6 h | MMP↑, caspase-3/7↓ | Park et al. (2018) |
| Curcuma Longa L. extract | - | SD rat | Male | 200–225 g | MCAO (1 h)/R (24 h) | intraperitoneal injection | 250 mg/kg | Prevention | 30 min before MCAO | ROS↓, caspase-3↓, cleaved caspase-3↓, Cyt-c↓, p53↓, Bax↓, Bcl-2↑ | |
| Lycium barbarum L. polysaccharide | - | ICR mice | Male | 20–25 g | MCAO (2 h)/R (24 h) | intragastric administration | 10, 20, 40 mg/kg | Prevention | Pretreatment for 7 days, q.d. | caspase-3↓, Bax↓, Cyt-c↓, Bcl-2↑, Caspase-9↓, cleaved PARP-1↓ | Wang et al. (2014b) |
| Angelica sinensis (Oliv.)Diels extract | - | SD rat | Male | 300–350 g | MCAO (1 h)/R (1/3 days) | intraperitoneal injection | 0.25, 0.5, 1 g/kg | Prevention | 30 min before MCAO | p-Bad/Bad↑, Cyt-c↓, cleaved caspase-3↓ | |
| extract of Scrophularia ningpoensis Hemsl. | - | Kunming mice | Male | 18–22 g | MCAO (2 h)/R (24 h) | intragastric administration | 2.4 g/kg-1 | Prevention | 7 days, q.d., before MCAO | LDH↓, MDA↓,NO↓, Bax↓, Bcl-2↑ | Meng et al. (2018) |
| Dengzhanxixin injection (Dengzhanxixin Zhusheye in Chinese pharmacopoeia) | - | SD rat | Male | 270 ± 10 g | MCAO (1.5 h)/R (24 h) | intravenous injection | 8.8 mg/kg | treatment | 7 days, bid, after MCAO | Infarct volume↓, the survival of neuronal cells↑, modulated the mitochondrial respiratory chain process | |
| Ganoderma lucidum (Leyss.ex Fr.) Karst. polysaccharides | primary cortical neuronal cell; OGD(2 h)/R (24 h) | - | - | - | - | treated with Ganoderma lucidum (Leyss.ex Fr.) Karst. | 0.1,1,10 ug/ml | treatment | 30 min before OGD, during the OGD period and afterward until different times after OGD exposure | caspase-3↓,caspase-8↓,caspase-9↓,Bax↓, Bcl-2↑,LDH↓ | Zhou et al. (2010) |
| polysaccharides | |||||||||||
| Ganoderma lucidum (Leyss.ex Fr.) polysaccharides | - | SD rat | Male | 280–300 g | MCAO/R (1.5 h) | intragastric administration | 100,200,400 mg/kg | treatment | Pretreatment for 7 days, q.d., and administration was continued until sacrifice at conclusion of the experiment | TUNEL-positive staining↓ | Zhou et al. (2010) |
| Cordyceps sinensis (BerK.) Sacc. extract | - | SD rat | Male | 250 ± 10 g,25 ± 5 g | MCAO/R | take orally | 1.0 g/kg | treatment | after ischemia for 24 h, every 24 h for three times | OFR↓,Cyt-c↓,ATP↑, COX↑, complexes I-IV↑,Bax↓,caspase-3↓ | |
| Curcuma Longa L. extract | - | SD rat | Male | - | MCAO/R | take orally | 500 mg/kg | treatment | After ischemia for 4 h | NO↓, ROS↓, iNOS↓, eNOS↓,Cyt-c↓,Bax↓, Bcl-2↑,caspase-3↓, peroxynitrite↓ | |
| Angelica sinensis (Oliv.) Diels polysaccharides | - | SD rat | Male | 200–250 g | MCAO (2 h)/R | intravenous injection | 200 mg/kg | treatment | 2, 26, 50, 74, 98, 122, 146 h after MCAO | SOD↑,GSH-px↑, MDA↓, MMP↑ | Lei et al. (2014) |
| Cordyceps sinensis (BerK.) Sacc. extract | Primary BMECs; OGD/R | - | - | - | - | treated with Cordyceps sinensis (BerK.) Sacc. extract | 5,10 or 20 μg/ml | treatment | 12 h before and during OGD | MMP↑,Bax↓,Cyt-c↓, caspase-3↓,Bcl-2↑, caspase-8↓,caspase-9↓ | |
| Angelica sinensis (Oliv.) Diels polysaccharides | PC12 cells; H2O2-induced | - | - | - | - | treated with Angelica sinensis (Oliv.) Diels polysaccharides | 0.1–0.8 mg/mL | treatment | Pretreatment for 15 min, 24 h after H2O2 | ROS↓,MMP↑,SOD↑, GSH-Px↑,MDA↓ | Lei et al. (2014) |
| Lycium barbarum L. polysaccharide | Primary Cortical Neuron cells; OGD(4 h)/R (24 h) | - | - | - | - | treated with Lycium barbarum L. polysaccharide | 100 mg/ml | treatment | 24 h after OGD | Bad↓, Cyt-c↓, cleaved caspase-3↓, Ca2+↓ | Shi et al. (2017) |
| Lycium barbarum L. polysaccharide | Primary hippocampal neuronal cells; OGD(4 h)/R (24 h) | - | - | - | - | treated with Lycium barbarum L. polysaccharide | 10,20,40 mg/l | treatment | at the start of the reperfusion phase | ROS↓, Ca2+↓, MMP↑, LDH↓ | Zhao et al. (2017) |
| Lycium barbarum L. polysaccharide | - | Wister rats | Male | 220–300 g | CCAs(15 min)/R (1 week) | intragastric administration | 20 mg/kg | treatment | 1 week before and after ischemia | CA1 neurons↓ | Shi et al. (2017) |
| extract of Ginkgo biloba L. | - | SD rat | Male | 260–280 g | MCAO (2 h)/R (24 h) | intraperitoneal injection | 50 mg/kg | treatment | 24 h after MCAO, 14days, q.d. | Bec-1↑,LC3-Ⅱ↑, AMPK↑, mTOR↑, ULK1↑,Parkin↑, Drp1↑,Opa1↑,Bcl-2/Bax↑ | Li et al. (2019) |
| The combination of Panax ginseng C.A.Mey. and Angelica sinensis (Oliv.)Diels | - | SD rat | Male | 250–300 g | MCAO (2 h)/R | intragastric administration | 4.5.9 g/kg | treatment | 3 days before MCAO,q.d., 7 days after MCAO,q.d. | Drp1↓, NLRP3↓, GSDMD↓ | Hu et al. (2020) |
| ginsenoside Rd and LIG | BV-2 microglial cells; OGD(2 h)/R (24 h) | - | - | - | - | treated with ginsenoside Rd and LIG | Rd (0.1, 1.0, 10 μmol/l), LIG (1, 2.5, 10 μmol/l) | Prevention | 2 h before OGD/R | Drp1↓, LDH↓, NLRP3↓, | Hu et al. (2020) |
| GSDMD↓ |
The molecular mechanism of herbal extracts in the treatment of ischemic stroke by targeting mitochondria.
Notes: ↑, upregulate; ↓, downregulate; EC: energy charge; p-JNK1/2: Phosphorylated c-June N-terminal kinase1/2; T-NOS: total nitric oxide synthase; Fas: Frame alignment signal; FasL: frame alignment signal ligand; MMP-9: Matrix metalloproteinases 9; COX-2: Cyclooxygenase-2; CAT: catalase; GSH-Px: Glutathione peroxidase; GSSG: glutathione disulfide; Bec-1: Beclin-1; p53/Puma: 53 Up-regulatory Modulator of Apoptosis; Cleaved PARP: Cleaved poly ADP-ribose polymerase; OFR: oxygen free radical; COX: cytochrome c oxidase; eNOS: endothelial nitric oxide synthase; NLRP3: Nod-like receptor protein 3; GSDMD: Gasdermin D; ULK1, Unc-51-like kinase 1; LC3-Ⅱ, Light chain 3-Ⅱ; iNOS, inducible nitric oxide synthase; LDH, lactate dehydrogenase; GSH, glutathione; SQSTM1, Sequestosome-1; SD, Sprague-Dawley; MCAO/R, middle cerebral artery occlusion/reperfusion; q. d., once a day; bid, two times 1 day; BMECs, bone marrow endothelial cells; CCA, common carotid artery; CCA/R, common carotid artery/reperfusion; LIG, Z-ligustilide.
FIGURE 3
3.3 TCM compounds and their molecular mechanisms by regulating mitochondria in treating ischemic stroke
3.3.1 TCM compound pretreatment in regulating mitochondria of ischemic stroke
Herbal medications have yielded many active compounds for treating ischemic stroke, and this number is increasing as research progresses. Based on published literature, we analyzed 34 TCM compounds and their molecular mechanisms in regulating mitochondria in ischemic stroke. Mitochondria appeared swollen with irregular, disrupted membranes and poorly defined cristae in an MCAO rat model. However, these mitochondrial abnormalities were prevented by piperine pretreatment (Kaushik et al., 2021). In vitro, OGD/R induced mitochondrial fragmentation, mitochondrial enlargement, mitochondrial number reduction, and mitochondrial swelling, which could be alleviated by pretreatment with notoginsenoside R1 (Zhu et al., 2021; Liu et al., 2022), hydroxysafflor yellow A (Huang et al., 2021), and calenduloside E (Li et al., 2022b). Ginsenoside Rd and piperine pretreatment improved mitochondrial energy metabolism after cerebral I/R injury (Ye et al., 2011; Kaushik et al., 2021) whereas notoginsenoside R1 and notoginseng leaf triterpene pretreatment improved mitochondrial energy metabolism after OGD/R injury (Xie et al., 2020; Zhu et al., 2021; Liu et al., 2022). In vivo (Ye et al., 2011; Mukherjee et al., 2019; Zhang et al., 2019; Huang et al., 2021; Kaushik et al., 2021) and in vitro (Li et al., 2017; Wu et al., 2017; Zhou et al., 2017; Huang et al., 2020; Xie et al., 2020; Li et al., 2021; Huang et al., 2021; Li et al., 2022b; Ni et al., 2022; Peng et al., 2022) studies have reported that TCM compounds (e.g., piperine, ginsenoside Rd, hydroxysafflor yellow A, β-patchoulene, curcumin, ginsenoside Rb1, artemether, notoginseng leaf triterpenes, ginkgolide k, ginsenoside monomer compound k, tanshinone IIA, artemisinin, and kaempferol) inhibited oxidative stress and mPTP and upregulated MMP levels. In vitro studies show that atractylenolide III, ginkgolide K, calenduloside E, and kaempferol decreased Drp1 translocation from the cytosol to the outer mitochondrial membrane, reduced its phosphorylation at Ser616, and enhanced its phosphorylation at Ser637 (Wu et al., 2017; Zhou et al., 2017; Zhou et al., 2019; Li et al., 2022b). In addition, ginsenoside Rb1 inhibits astrocyte activation and promotes the transfer of astrocytic mitochondria to neurons against ischemic stroke in vitro (Ni et al., 2022). Chrysophanol and ginsenoside monomer compound K decreased the level of mitochondrial autophagy in MCAO mice after I/R injury and in neurons after OGD/R injury, respectively (Huang et al., 2020; ) by inhibiting the AMPK/mTOR pathway (Huang et al., 2020). In contrast, kaempferol potentiated autophagy in primary neurons after OGD/R injury (Wu et al., 2017). Much evidence in vivo (Ye et al., 2011; Mukherjee et al., 2019; Zhang et al., 2019; Kaushik et al., 2021) and in vitro (; Li et al., 2017; Zhou et al., 2017; Huang et al., 2020; Huang et al., 2021; Li et al., 2022b; Peng et al., 2022) suggests that TCM compounds (e.g., piperine, ginsenoside Rd, β-patchoulene, curcumin, hydroxysafflor yellow A, ginkgolide K, ginsenoside monomer compound K, tanshinone IIA, calenduloside E, artemisinin, and paeoniflorin) have protective effects against cerebral I/R injury or OGD/R injury by inhibiting mitochondria-mediated apoptosis.
In summary, TCM compounds can alleviate abnormal mitochondrial structure, improve mitochondrial energy metabolism, decrease the expression and translocation of Drp1, reduce oxidative stress, mPTP, and mitochondria-dependent apoptosis, upregulate MMP, and promote the transfer of astrocytic mitochondria to neurons to prevent ischemic stroke. However, mitophagy results remain controversial and require further investigation (Figure 4).
FIGURE 4
3.3.2 The effect of TCM compounds after ischemic stroke in regulating mitochondria
Protocatechudehyde and ligustilide improved mitochondrial morphology after cerebral I/R injury in vivo (Zeng et al., 2021a; Mao et al., 2022) whereas hydroxysafflor yellow A maintained mitochondrial morphology after OGD injury in vitro (). Protocatechudehyde, curcumin, and ligustilide protect against cerebral ischemic injury by improving mitochondrial energy metabolism (Wang and Xu, 2020; Zeng et al., 2021a; Mao et al., 2022). Curcumin could also alleviate OGD injury by improving mitochondrial energy metabolism (Wang and Xu, 2020). Evidence from in vivo studies (Zhang et al., 2017; Zhao et al., 2018b; Mondal et al., 2019; Wang and Xu, 2020; Li et al., 2021; ; Mao et al., 2022; Peng et al., 2022) and in vitro studies (; Liu et al., 2018; ; Xiang et al., 2019; Xue et al., 2019; Wang and Xu, 2020; Wei et al., 2021; Ye et al., 2021; Mao et al., 2022) demonstrated that, following cerebral I/R injury or OGD injury, TCM compounds (e.g., curcumin, bilobalide, artemether, quercetin, artemisinin, tetrahydrocurcumin, rhein, ligustilide, icariside II, hydroxysafflor yellow A, oxymatrine, ginkgolide K, resveratrol, and astragaloside IV) alleviated oxidative stress, inhibited mPTP, and upregulated MMP levels. Mfn-1 and Drp-1 downregulation after cerebral I/R injury was restored by tetrahydrocurcumin treatment (Mondal et al., 2019) whereas Drp-1 downregulation and Opa1 upregulation after OGD injury were restored by hydroxysafflor yellow A treatment (). However, treating mice with ginkgolide K and calenduloside E prevents Drp1 translocation to the mitochondria and attenuates mitochondrial dysfunction after MCAO (Zhou et al., 2017; Li et al., 2022b). Curcumin and ligustilide enhanced cerebral I/R- or OGD-induced mitophagy (upregulating PINK1, Parkin, the colocalization of LC3B and mitochondrial markers, and the ratio of LC3-II to LC3-I) in vivo and in vitro (Wang and Xu, 2020; Mao et al., 2022). However, oxymatrine attenuates excessive autophagy (downregulating LC3 and Beclin-1) in vivo and in vitro by activating the PI3k/Akt pathway (Wei et al., 2021). Additionally, picroside II attenuated cerebral I/R injury by inhibiting EndoG release from the mitochondria into the cytoplasm (Li et al., 2018) Similarly, baicalein treatment decreased cerebral I/R injury by inhibiting nuclear translocation of AIF in cerebral I/R rats (Li et al., 2020). Many in vivo (Zhang et al., 2017; Zhao et al., 2018b; ; Yin et al., 2020; Li et al., 2021; Zhang et al., 2021; Li et al., 2022b; Peng et al., 2022) and in vitro (Zhao et al., 2018a; ; Liu et al., 2018) studies have shown that TCM compounds (e.g., curcumin, artemether, ferulic acid, artemisinin, rhein, astragaloside IV, l-borneol, calenduloside E, ginkgolide K, dehydrocostus lactone, and icariside II) exert protective effects in MCAO animal models or OGD/R cell models by inhibiting BAX/BCL2, caspase-9, caspase-3, cleaved caspase-3, caspase-8, Cyt-c, Bid, Apaf-1, Bad, and p53 (Figure 4).
Through in-depth comparative analysis, TCM compounds provided during pretreatment and treatment could alleviate abnormal mitochondrial structure; inhibit oxidative stress, mPTP opening, and Drp1 translocation to the mitochondria; and improve mitochondrial energy metabolism and MMP. TCM compounds provided pretreatment could promote the transfer of astrocytic mitochondria to neurons and potentiate autophagy and also decrease the level of mitochondrial autophagy by inhibiting the AMPK/mTOR pathway. Meanwhile, TCM compounds during treatment could maintain the dynamic balance between mitochondrial fission and fusion, inhibit mitochondrial autophagy by activating the PI3k/Akt pathway, promote mitophagy by activating PINK1/Parkin, inhibit Endo G and AIF release from mitochondria into the cytoplasm, and further attenuate mitochondria-mediated apoptosis. The specific mechanisms of these compounds in vivo and in vitro are shown in Table 3; Figure 3.
TABLE 3
| Agents | Sources | Cell lines and cell models | Animals | Gender | Weight | Animal model | Routes | Dose | Prevention/treatment | Time periods | Mechanisms | References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Piperine | Piper nigrum L. | - | Wistar rats | Male | 250–300 g | tMCAO (90 min)/R (22.5 h) | take orally | 10 mg/kg | Prevention | 15 days before tMCAO, qd | Cyt-c↓, caspase 3↓, Bax↓, Bcl-2↑, BDNF↑, CREB↑ | Kaushik et al. (2021) |
| Notoginsenoside R1 | Panax notoginseng (Burk.) F. H. Chen | HBMEC cells; OGD(2.5 h)/R (12 h) | - | - | - | - | treated with Notoginsenoside R1 | 6.26–100 μM | Prevention | 12 h before OGD/R | NICD↓, DLL4↓, Hes1↓, Hey1↓ | Zhu et al. (2021) |
| Notoginsenoside R1 | Panax notoginseng (Burk.) F.H.Chen | Neuro2a cells, OGD(5% CO2 and 95% N2, 2h; 10% CCK-8 solution for 2 h) | - | - | - | - | treated with Notoginsenoside R1 | 5, 10, 20, 100 and 200 μM | Prevention | Before the OGD | cell viability↑, MMP↑, Atp12a↑, Atp6v1g3↑ | Liu et al. (2022) |
| Hydroxysafflor yellow A | Carthamus tinctorius L. | Primary BMECs; OGD(2 h)/R (24 h) | - | - | - | - | treated with Hydroxysafflor yellow A | 80 um | Prevention | 2 h or 30 min before OGD/R | MMP↑, ROS↓, mPTP↓ | Huang et al. (2021) |
| Calenduloside E | Aralia elata (Miq.) Seem. | The HT22 cells; OGD(0, 2, 4, 6, or 8 h)/R (24 h) | - | - | - | - | treated with Calenduloside E | 1, 2, 4, 8 μg/mL | Prevention | 4 h before OGD/R | Drp1↓, p-Drp1(Ser637)↑, ROS↓, Ca2+↓, Bax↓, Cleaved-caspase3↓, Cleaved-caspase9↓, Cyt-c↓,Bcl-2↑, caspase3↑, caspase9↑ | Li et al. (2022b) |
| Ginsenoside Rd | Panax ginseng C. A. Mey. | - | SD rat | Male | 270–320 g | MCAO/R (4/24 h) | Intraperitoneal Injections | 50 mg/kg | Prevention | 30 min before MCAO | ETC.,↑, complex I↑, complex III↑, complex IV↑, MMP↑, ROS↓ | Ye et al. (2011) |
| Ginsenoside Rd | Panax ginseng C. A. Mey. | Non-synaptosomal mitochondria; OGD/R | - | - | - | - | - | - | - | - | MMP↑, ROS↓, cleaved caspase-3↓, Cyt-c↓, AIF↓ | Ye et al. (2011) |
| Hydroxysafflor yellow A | Carthamus tinctorius L. | - | SD rat | Male | 240–250 g | MCAO/R (24 h) | Intravenous Injections | 5 mg/kg | Prevention | 30 min before MCAO | ROS↓, Cyt-c↓, ATP↑, mPTP↓, Cyp D↓, MEK↓, ERK↓ | Huang et al. (2021) |
| β-patchoulene | Pogostemon cablin (Blanco)Benth. | - | SD rat | Male | 80–120 g | MCAO (2 h)/R (24 h) | Intravenous Injections | 10 mg/kg | Prevention | Pretreatment for 1 h | Bax/Bcl-2↓, casapase-3↓, MMP↑, SOD↑, GSH-px↑ | Zhang et al. (2019) |
| Curcumin | Curcuma Longa L. | - | SD rat | Male | 415–440 g | CIR(30 min)/R (6 h) | Intragastric administration | 5 mg/kg | Prevention | 24 h before the induction of CIR | ROS↓, SDH↑, NADH↓, SOD↑, CAT↑ | Mukherjee et al. (2019) |
| Notoginseng leaf triterpenes | Panax notoginseng (Burk.) F. H. Chen | SH-SY5Y cells; OGD/R | - | - | - | - | treated with Notoginseng leaf triterpenes | 1.56–100 μg/mL | Prevention | 24 h before OGD/R | ROS↓, MMP↑, ATP↑, NAD+↑, NADH↑, SIRT1/2/3↑, NAMPT↑, p-Foxo3a↑, PGC-1α↑, MnSOD↑ | Xie et al. (2020) |
| Ginsenoside Rb1 | Panax ginseng C. A. Mey. | Primary astrocytes; OGD(4 h)/R (1 h) | - | - | - | - | treated with Ginsenoside Rb1 | 0.1, 1, 10 µm | Prevention | before OGD/R | ROS↓, LDH↓, GS↑, GAPDH↓, GSH↑, NADPH↑ | Ni et al. (2022) |
| Artemether | Artemisia annua L. | PC12 cells; OGD(2, 4, 6, 8 h)/R (16, 18, 20, 22 h) | - | - | - | - | treated with Artemether | 10–100 μM | Prevention | 2 h before OGD/R | ROS↓, MMP↑, Bax/Bcl-2↓ | Li et al. (2021b) |
| Ginkgolide K | Ginkgo biloba L. | neuroblastoma Neuro2a cells; OGD(4 h)/R (1 h) | - | - | - | - | treated with Ginkgolide K | 40 μM | Prevention | 4 h before OGD/R | ROS↓, Drp1↓, Calcein-AM↑, mPTP↓, GSK-3β↓, MMP↑, Ca2+↓, Cyt-c↓, p-Drp1(Ser637)/Drp1↑, Drp1/COX-4↓ | Zhou et al. (2017) |
| Ginsenoside monomer compound K | Panax ginseng C. A. Mey. | PC12 cells; OGD(2, 8 h)/R (4–24 h) | - | - | - | - | treated with Ginsenoside monomer | 2, 4, 8 µM | Prevention | Pretreatment for 48 h | ROS↓, Ca2+↓, MMP↑, Bcl-2/Bax↑, Cleaved PARP↓, Atg5↓, LC3-II↓, Atg7↓, P-AMPK/AMPK↓, P-mTOR/mTOR↑ | Huang et al. (2020) |
| compound K | ||||||||||||
| Tanshinone IIA | Salvia miltiorrhiza Bge. | SH-SY5Y cells; 10 μL L-glutamate, 24 h | - | - | - | - | treated with Tanshinone IIA | 2.5–10.0 μM | Prevention | Pretreatment for 24 h | ROS↓, MDA↓, Xanthine oxidase↓, SOD↑, CAT↑, MMP↑,ATP↑, Bcl-2↑, Bax↓, cleaved caspase-3↓, JNK↓, p38 MAPK↓ | Li et al. (2017) |
| Artemisinin | Artemisia annua L. | PC12 cells; OGD(4 h)/R (20 h) | - | - | - | - | treated with Artemisinin | 6.25–50 μM | Prevention | Pretreatment for 2 h | ROS↓, MMP, ERK1/2/CREB↑, Cyt-c↓, caspase 3↓, LDH↓ | Peng et al. (2022) |
| Kaempferol | Kaempferia galanga L. | neuroblastoma Neuro2a cells; OGD(2 h)/R (2 h) | - | - | - | - | treated with Kaempferol | 10 μM | Prevention | before OGD/R | SDH↓, Drp1↓, p-Drp1(Ser637)/Drp1↑, PAS/Drp1↑, Akt↑, PAS↑, mPTP↓, MMP↑, LC3-II/I↑, p62↑, Atg5↓ | Wu et al. (2017) |
| Chrysophanol | Rheum palmatum L. | - | Kunming mice | Male | 18–22 g | CCA(5 min)/R (24 h) | Intraperitoneal Injections | 0.1, 1, 10 ml/kg | Prevention | Pretreatment for 10 days, 30 min before CCA | LC3B-II↓, LC3B-I↓, NIX↓, LC3B↓, LC3B-II/LC3B-I↓ | |
| Atractylenolide III | Atractylodes macrocephala Koidz. | BV2 microglial cells; OGD/R (48) | - | - | - | - | treated with Atractylenolide III | 0.01–100 μM | Prevention | cells were incubated with Atractylenolide III, followed by treatment with OGDR for 48 h | p-JAK2A↓, P-STAT3↓, P-Drp1 (Ser616)↓, P-Drp/Drp1↓, Drp/COX-4↓ | Zhou et al. (2019) |
| Paeoniflorin | Paeonia lactiflora Pall. | PC12 cells; glutamate-induced (24 h) | - | - | - | - | treated with Paeoniflorin | 100, 200, 300 μ M | Prevention | Pretreatment for 24 h | LDH↓, Bax↓, p-Bad↓, Bcl-2↑, Bcl-xL↑, caspase-3↓, caspase-9↓, cleaved PARP↓ | |
| L-borneol | Cinnamomum camphora (L.) Presl | - | SD rat | Male | 240–280 g | pMCAO | Intragastric administration | 0.2, 0.1 and 0.05 g/kg | treatment | for 2 days before model establishment and for 1 day after model establishment | Cyt-c↓, Apaf-1↓, Bad↓, cleaved Caspase-3↓,Bcl-2↑, MEP↓, IDH2↓, MCU ↓, Apaf-1↓ | Zhang et al. (2021) |
| Curcumin | Curcuma Longa L. | - | SD rat | Male | - | MCAO | Intraperitoneal Injections | 100 mg/kg | treatment | once at the onset of cerebral reperfusion | ROS↓, MMP↑, ATP↑, LC3B↑, LC3-II↑ | Wang and Xu (2020) |
| Curcumin | Curcuma Longa L. | Cortical Neurons; OGD(5% CO2 and 95% N2, 2 h)/R (at normal conditions, 24 h) | - | - | - | - | treated with Curcumin | 5 μM | treatment | once at the stage of reoxygenation | ROS↓, MMP↑, ATP↑, LC3-II/LC3-I ↓ | Wang and Xu (2020) |
| Protocatechudehyd | Acacia catechu (L. f.) Willd. | - | SD rat | Male | 260 ± 20 g | tMCAO (30min)/R (7 days) | Intravenous Injections | 20, 40 and 80 mg/kg | treatment | 6 h after reperfusion, treatment once daily for 1 week | infarct volume↓, cell death↓, PDK1+↓, pPDHA1↓, acetyl CoA↑, ATP↑ | Zeng et al. (2021a) |
| Ligustilide | Ligusticum chuanxiong Hort. | - | SD rat | Male | 240–280 g | MCAO (2 h)/R (72 h) | Intraperitoneal Injections | 10 and 20 mg/kg | treatment | at the onset of reperfusion, qd, for 3 days | mt-Atp6/Rpl13↓, Tomm20↓, COX4I1↓, p62↓, LC3-II/LC3-I↑, PINK1↑, Parkin↑, ROS↓, Na+ -K+ -ATPase↑ | Mao et al. (2022) |
| Ligustilide | Ligusticum chuanxiong Hort. | HT-22 cells; OGD(5%CO2 and 95% N2, 2 h)/R (a three-gas incubator, 24 h) | - | - | - | - | treated with Ligustilide | 20 μM | treatment | at the time of reperfusion | Parkin↑, PINK1↑, LC3-II/LC3-I↑, ROS↓ | Mao et al. (2022) |
| Hydroxysafflor yellow A | Carthamus tinctorius L. | Similar to the primary mouse neuronal cells; OGD(5% CO2 and 95% N2, 12 h/R (5% CO2 at 37°C for 20 h) | - | - | - | - | treated with Hydroxysafflor yellow A | 1 and 10 μM | treatment | exposed to OGD for 120 min, and treated with Hydroxysafflor yellow A for 20 h | c-cleaved Caspase-3↓, p-Akt↑, BCL2 ↑, Nerve nucleus↑, phenylalanine↓, Got1↑, ROS↓, Drp1↑ | |
| Curcumin | Curcuma Longa L. | - | albino rats | Male | 180–200 g | MCAO (30min)/R | Intraperitoneal Injections | 25 mg/kg | treatment | Single dose after reperfusion | Bax↓, Bcl-2↑, p53↓, Sirt1↑, IL-6↓, TNF-α↓, MMP↓ | Zhang et al. (2017a) |
| Quercetin | Eucommia ulmoides Oliv. | - | SD rat | Male | 250–300 g | MCAO (2 h) | Intraperitoneal Injections | 5 mg/Kg Quercetin | treatment | Two hours after MCAO | ROS↓, H2O2↓, MDA↓, GSH-Px↑, CAT↑, SOD ↑ | |
| Intravenous Injections | 0.75, 2.5, 5 and 7.5 mg/Kg HA-QT | |||||||||||
| Tetrahydrocurcumin | Curcuma Longa L. | - | C57BL/6J mice | Male | 28–33 g | MCAO (40 min)/R (72 h) | Intraperitoneal Injections | 25 mg/kg | treatment | after 4 h of ischemia. 1 time every day, lasting for 3 days | Blood-brain Barrier permeability↓, MnSOD↑, ATP↑, LC3-II↓, Mfn-1↑, Drp-1↑, DNMT1↓, DNMT3a↓, DNMT↓ | Mondal et al. (2019) |
| Icariside II | Epimedium brevicornu Maxim. | PC12 cells; OGD(5% CO2 and 95% N2, 2 h)/R (5% CO2 and 95%air, 24 h) | - | - | - | - | treated with Icariside II | 12.5, 25 and 50 μM | treatment | After deprivation of glucose and hypoxia, for 24 h | LDH↓, ROS↓, nucleus Nrf2↑, cytoplasm Nrf2 ↓, Bcl-2↑, Bax↓, Caspase-3↑, SIRT3↑, IDH2↑ | |
| Oxymatrine | Sophora flavescens Ait. | - | SD rat | Both | 12–17 g | Rice-Vannucci (hypoxia for 2.5 h) | Intraperitoneal Injections | 120 mg/kg | treatment | After 48 h modeling, injected at 12 h intervals for 2 days | Beclin-1↓, LC3↓, P62↑, p-PI3K↑, p-Akt↑ | Wei et al. (2021) |
| Oxymatrine | Sophora flavescens Ait. | The primary hippocampal neurons; OGD(5% CO2 and 95% N2, 2 h)/R (at normal conditions, 24 h on day 7) | - | - | - | - | treated with Oxymatrine | 5 μ g/ml | treatment | After the OGD, for 24 h | neuronal apoptosis↓, Cell viability↑, Beclin-1↓, LC3↓, P62↑, PI3K ↑, Akt ↑, mTOR↑ | Wei et al. (2021) |
| Astragaloside IV | Astragalus membranaceus (Fisch.) Bge. | Fetal cerebral cortical neuron; OGD(1%O2, 5% CO2, and saturated humidity, 3 h)/R (95% air and 5% CO2, 24 h) | - | - | - | - | treated with Astragaloside IV | 25, 12.5 and 6.25 μmol/L | treatment | At the start of OGD, throughout the OGD and reoxygenation | LDH↓, Caspase-3↓, MMP↑, ATP ↓, ROS↑, PKA/CREB↑ | Xue et al. (2019) |
| Ginkgolide K | Ginkgo biloba L. | SH-SY5Y cells; OGD(5% CO2 and 95% N2, 4 h)/R (5% CO2 and 95% O2,1and 24 h) | - | - | - | - | treated with Ginkgolide K | 12.5, 25 and 50 μg/ml | treatment | After OGD 4 h, for 1 h | cell viability ↑, ROS↓, MMP ↓, p-p38↓, p -JNK↓, p-p53 ↓, p-c-Jun ↓, Bax↓, Bcl-2↑, cleaved Caspase-9↓, c-cleaved Caspase-3↓, | Liu et al. (2018) |
| Resveratrol | Morus alba L. or Polygonum cuspidatum Sieb. et Zucc. | Rat cortical neurons,OGD(1%O2, 5% CO2, and saturated humidity, 4 h)/R (at normal conditions, 2 h) | - | - | - | - | treated with Resveratrol | 1–30 μM(10 μM) | treatment | After the OGD | Caspase-3↑, ROS↓, MMP↑, LC3B-II↓, TIMM23↑, TOMM20↑, PinK1↑, Parkin↑ | Ye et al. (2021) |
| Bilobalide | Ginkgo biloba L. | Astrocytes; OGD(5% CO2 and 95% N2, 2.5 h)/R (at normal conditions, 3, 6, and 12 h) | - | - | - | - | treated with Bilobalide | 25, 50, and 100 μ M | treatment | After the OGD | ROS ↓, MMP↑, MnSOD↑ | Xiang et al. (2019) |
| Picroside II | Picrorhiza scrophulariiflora Pennell | - | Wistar rat | Male | 240–260 g | MCAO (2 h)/R (24 h) | Intraperitoneal Injections | 20 mg/kg | treatment | 2 h after MCAO | Infarct volume↓,VDAC1↓, EndoG↓, ROS↓ | Li et al. (2018b) |
| Baicalein | Scutellaria baicalensis Georgi | - | SD rat | Male | 240–260 g | MCAO (60min)/R (7 days) | Intragastric administration | 100 mg/kg | treatment | After 60 min MCAO,qd, for 7days | NRP1↓, Cyt-c↓, PARP-1↓, AIF↓ | Li et al. (2020) |
| Ferulic acid | Cinnamomum cassia Presl | - | SD rat | Male | 300–350 g | pMCAO | Intravenous Injections | 60, 80 and 100 mg/kg | treatment | after MCAO | p -Akt/Akt ↑, p-mTOR/mTOR ↑, Bcl-2/Bax ↑, Cyt-c↓, c-cleaved Caspase-3↓, TUNEL-immunoreactive cells↓ | |
| Astragaloside-IV | Astragalus membranaceus (Fisch.) Bge. | - | SD rat | Male | 280 ± 20 g | MCAO (60min)/R (7 days) | Intragastric administration | 12.5, 25 and 50 mg/kg | treatment | after the reperfusion, qd. for 7days | infarct volume↓, Fas↓, FasL↓, Bcl-2/Bax ↑, Caspase-8↓, Cyt-c↓, Bid↓, Caspase-3↑, PARP-1↓ | Yin et al. (2020) |
| Dehydrocostuslactone | Aucklandia lappa Decne. | hippocampal slice; OGD/R | - | - | - | - | treated with Dehydrocostuslactone | 1,5, 10 µM | treatment | within the OGD/R period | LDH↓, Bcl-2↑, Bax↓, Cyt-c↓, apaf-1↓, caspase-9↓, caspase-7↓, caspase-3↓, SQSTM1↓, Lc3↓ | Zhao et al. (2018a) |
| Rhein | Rheum palmatum L. | - | SD rat | Male | 260–300 g | MCAO (2 h)/R (72 h) | take orally | 25, 50, 100 mg/kg | treatment | after MCAO/R, qd for 3 days | MDA↓, SOD↑, GSH-px↑, CAT↑, Bax↓, Bcl-2↑, caspase-9↓, caspase-3↓, cleaved caspase-3↓ | Zhao et al. (2018b) |
The molecular mechanism of TCM compounds in the treatment of ischemic stroke by targeting mitochondria.
Notes: ↑, upregulate; ↓, downregulate; SD, Sprague-dawley; tMCAO, transient Middle Cerebral Artery Occlusion; qd, once a day; BDNF, brain derived neurotrophic factor; CREB, cAMP, response element binding protein; NICD, Notch1 intracellular domain; CCK-8, Cell Counting Kit-8; Atp6v1g3, ATPase H + Transporting V1 Subunit H; BMECs, Brain Microvascular Endothelial Cells; p-Drp1(Ser637), Phosphorylated Drp1; ETC., electron transport chain; Cyp D, Cyclophilin D; MEK, Mitogen-activated protein kinase; ERK, extracellular regulated protein kinases; ERK1/2, Extracellular regulated protein kinases 1/2; GSH-px, glutathione-peroxidase; CIR, Cerebral ischemia-reperfusion; SDH, succinate dehydrogenase; CAT, catalase; NAD, nicotinamide adenine dinucleotide; SIRT1/2/3, sirtuin 1/2/3; NAMPT, nicotinamide phosphoribosyltransferase; p-Foxo3a, Phosphorylated Foxo3a; MnSOD, mitochondrial superoxide dismutase; LDH, lactate dehydrogenase; GS, glutamine synthetase; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; GSH, glutathione; NADPH, nicotinamide adenine dinucleotide phosphate; GSK-3β, Glycogen synthase kinase-3β; COX-4, Cyclooxygenase-4; Atg5/7, Autophagy-related gene proteins 5/7; LC3-I/Ⅱ, Light chain 3I/Ⅱ; P-AMPK, Phosphorylation of AMP-activated protein kinase; P- mTOR, phosphorylation of mammalian target of rapamycin; JNK, c-Jun N-terminal kinase; PAS, phosphorylated akt consensus sequence; LC3B-I/II, light chain 3B I/II; LC3B, light chain 3B; p-JAK2A, Phosphorylated adipocyte-Specific Deletion of Janus Kinase 2; P-STAT3, Transcription 3; IDH2, isocitrate dehydrogenase2; MCU, mitochondrial calcium uniporter; pPDHA1, phosphonated Pyruvate Dehydrogenase E1 Subunit Alpha 1; acetyl CoA, acetyl coenzyme A; mt-Atp6, Mitochondrially Encoded ATP, Synthase Membrane Subunit 6; Rpl13, Ribosomal Protein L13; COX4I1, cytochrome c oxidase subunit 4I1; Got1, glutamic oxaloacetic transaminase1; IL-6, Interleukin-6; TNF-α, Tumor necrosis factor α; HA-QT, hyaluronic acid- Quercetin; DNMT1, DNA (cytosine-5-)-methyltransferase 1; DNMT3a, DNA (cytosine-5-)-methyltransferase 3a; DNMT, DNA (cytosine-5-)-methyltransferase; Nrf2, nuclear factor erythroid 2-related factor 2; LC3, Light chain 3; p-PI3K, Phosphorylation of phosphoinositide 3 kinase; p-Akt, Phosphorylation of protein kinase B; PKA, protein kinase A; TIMM23, Translocase Of Inner Mitochondrial Membrane 23; Tomm20, translocase of outer mitochondrial membrane 20 homolog; VDAC1, voltage-dependent anion channel 1; EndoG, endonuclease G; NRP1, Neuropilin-1; PARP, poly (ADP-ribose) polymerase; TUNEL, Terminal deoxynucleotidyl transferase mediated dUTP, biotin nick end labeling; Fas, Frame alignment signal; FasL, frame alignment signal ligand; SQSTM1, Sequestosome-1; HBMEC, human brain microvascular endothelial cells; Calcein-AM, calcein acetoxymethyl ester; Atp12a, ATPase H+/K+ transporting non-gastric alpha2 subunit; Na+–K+-ATPase, Sodium potassium ATPas; CCA, common carotid artery; PMCAO, perminent Middle Cerebral Artery Occlusion; HBMEC, human brain microvascular endothelial cells.
3.4 TCM prescription and its molecular mechanisms by regulating mitochondria in treating ischemic stroke
3.4.1 TCM prescription pretreatment for regulating mitochondria in ischemic stroke
Ischemic strokes are usually treated using TCM prescriptions owing to TCM’s overall concept of TCM and syndrome differentiation-based treatment. In MCAO rats, pretreatment with Xiao-Xu-Ming decoction improved the abnormal mitochondrial ultrastructure (Lan et al., 2018). Pretreatment with Buyang Huanwu decoction prevents H2O2-induced ultrastructural disruption of mitochondria in human umbilical vein endothelial cells, whereas Guhong injection preconditioning preserves mitochondrial morphology during OGD injury (Shen et al., 2016; Zhou et al., 2021). In human umbilical vein endothelial cells and primary cultured cortical neurons, H2O2 decreased ATP production, MDA levels, and MMP levels while increasing ROS and SOD levels, which could be reversed by pretreatment with Buyang Huanwu Decoction, Zhenbao pill, and YiQiFuMai Powder injection (Shen et al., 2016; Xu et al., 2017; Jia et al., 2021). In brain microvascular endothelial cells and primary cortical neurons, OGD/R induced MMP loss and oxidative stress injury, which could be alleviated by pretreatment with Guhong injection, Xingxiong injection, and Naoxintong capsules (Wang et al., 2021; Zhou et al., 2021; Zhu et al., 2022). Danhong injection pretreatment improved mitochondrial energy metabolism after OGD/R injury (Orgah et al., 2019). Xu et al. demonstrated that pretreatment with YiQiFuMai powder ameliorated H2O2-induced neuronal apoptosis by inhibiting mitochondrial dysfunction and PKCδ/Drp1-mediated excessive mitochondrial fission (Xu et al., 2017). Pretreatment with Xiao-Xu-Ming decoction and Zhenbao pill-containing serum exerted neuroprotective effects in MCAO rats and H2O2-induced vascular endothelial cells, respectively, by inhibiting mitophagy (Lan et al., 2018; Jia et al., 2021). In addition, Zhenbao pill-containing serum represses cell apoptosis by inhibiting autophagy (Jia et al., 2021). Xiao-Xu-Ming decoction inhibited the translocation of Smac/Diablo from the mitochondria to the nucleus, increased the level of cytoplasmic c-IAP1, and further inhibited ischemia-induced neuronal apoptosis (Lan et al., 2014). To date, many in vivo studies (e.g., Ershiwei Chenxiang pills, Pien-Tze-Huang and Xiao-Xu-Ming decoction) (Lan et al., 2014; Zhang et al., 2018; Hou et al., 2020) and in vitro studies (e.g., Buyang Huanwu decoction, Guhong injection, Xingxiong injection, YiQiFuMai powder injection, and Zhenbao pill) (Shen et al., 2016; Zhou et al., 2021; Zhu et al., 2022) have revealed that traditional Chinese prescriptions protect mitochondria from ischemic injury and inhibit the mitochondria-dependent apoptosis pathway.
In brief, TCM pretreatment improved abnormal mitochondrial structure, inhibited oxidative stress and mitophagy, improved mitochondrial energy metabolism and MMP, and maintained the dynamic balance of mitochondrial fission and fusion. TCM prescriptions inhibited Smac/Diablo release from the mitochondria into the cytoplasm and further attenuated mitochondria-mediated apoptosis (Figure 5).
FIGURE 5
3.4.2 The effect of TCM prescription after ischemic stroke in regulating mitochondria
Taohong Siwu decoction treatment for seven consecutive days decreased damage to mitochondrial structures following cerebral I/R injury (Ji et al., 2022). Treatment with Huang-Lian-Jie-Du decoction, Danhong injection, and Baoyuan capsule eliminated the inhibitory effect of cerebral I/R on mitochondrial metabolism in MCAO models (Wang et al., 2014; Zeng et al., 2021b; ). In vitro studies have also shown that Baoyuan capsule and Qing Nao Yi Zhi Fang improved mitochondrial energy metabolism after glutamate exposure or OGD/R injury (Zhang et al., 2000; ). Many in vivo (e.g., Danhong injection (Zeng et al., 2021b), Huang-Lian-Jie-Du-Decoction (Wang et al., 2014) and in vitro studies (e.g., Naoxintong (Ma et al., 2016), Shuxuetong injection (Sun et al., 2019), Mu-Xiang-You-Fang (Ma et al., 2020) and Tong Luo Jiu Nao injection (Li et al., 2014)) could downregulate mitochondrial oxidative stress levels and upregulate MMP levels in the MCAO rat and OGD/R cell models, respectively. YiQiFuMai powder injection inhibited the expression, phosphorylation, and translocation of Drp1 in oxidative stress-induced primary neurons and cerebral ischemia-injured rats, resulting in a significant improvement in cerebral infarction and neurological scores (Xu et al., 2017). Taohong Siwu decoction, Danhong injection, and ANNAO tablets upregulated the expression of autophagy markers (LC3-II/LC3-I and Beclin1) (Ji et al., 2022) and mitochondrial autophagy markers (Parkin (Orgah et al., 2019) and PINK1 (Zhang et al., 2020)) after cerebral I/R injury. Mu-Xiang-You-Fang inhibits autophagy after OGD/R-induced PC12 cell injury through the AMPK-mTOR pathway (Ma et al., 2020). Nan et al. reported that Gualou Guizhi decoction exerted its neuroprotective effects by inhibiting poly (ADP-ribose) translocation into mitochondria, thereby reducing the release and inhibiting the translocation of AIF and Endo G from mitochondria to the nucleus, which further inhibits ischemia-induced neuronal apoptosis (Nan et al., 2020). TCM prescriptions (e.g., Danhong injection (), Guhong injection (Zhou et al., 2021), YiQiFuMai powder injection (Xu et al., 2017), ANNAO tablets (Zhang et al., 2020), and Huang-Lian-Jie-Du decoction (Wang et al., 2019)) could downregulate pro-apoptotic factors (Cyt-c, cleaved-caspase-3, cleaved-caspase-9, Bad, Bax, and Bim) and upregulate anti-apoptotic factors (Bcl-2) after cerebral I/R injury in MCAO rats. Further, TCM prescriptions (e.g., Shuxuetong injection (Sun et al., 2019) and Naoxintong (Ma et al., 2016)) also downregulated pro-apoptotic factors (e.g., Cyt-c, cleaved-caspase-3, cleaved-caspase-9, and Bax) and upregulated anti-apoptotic factors (e.g., Bcl-2) after OGD/R injury (Figure 5).
In summary, TCM prescription pretreatment and treatment could improve the abnormal mitochondrial structure, mitochondrial energy metabolism, and MMP, and inhibit oxidative stress, mitochondrial fission, and mitophagy. Moreover, TCM prescription pretreatment inhibited Smac/Diablo release from mitochondria into the cytoplasm and further attenuated mitochondria-mediated apoptosis. In contrast, TCM prescription treatment promoted mitophagy by activating PINK1/Parkin and inhibiting mitochondria-mediated apoptosis by attenuating AIF and Endo G release from mitochondria into the cytoplasm. The specific mechanisms of the TCM prescriptions in vivo and in vitro are shown in Table 4; Figure 3.
TABLE 4
| Agents | Ingredients | Cell lines and cell models | Animals | Gender | Weight | Animal model | Routes | Dose | Prevention/treatment | Time periods | Mechanisms | References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xiao-Xu-Ming decoction | Ephedra sinica Stapf, Cassia obtusifolia L., Paeonia lactiflora Pall., Ligusticum chuanxiong Hort., Panax ginseng C. A. Mey., Cnidium monnieri (L.)Cuss., Scutellaria baicalensis Georgi, Dioscorea opposita Thunb., Lindera aggregate (Sims)Kos-term., Aconitum kusnezoffii Reichb., Glycyrrhiza uralensis Fisch., Saposhnikovia divaricata (Turcz.)Schischk., Coptis chinensis Franchet. | - | SD rat | Male | 250–280 g | MCAO (90 min)/R (24 h) | take orally | 60 g/kg | Prevention | Pretreatment 3 days, until the conclusion of the experiment. bid | Cell Injury↓, MDA↓, ATP↑,LC3B↓,VDAC1↓,LAMP1↓,Beclin1↓,p62↓ | Lan et al. (2018) |
| Buyang Huanwu Decoction | Astragalus membranaceus (Fisch.)Bge., Angelica sinensis (Oliv.)Diels, Paeonia lactiflora Pall., Ligusticum chuanxiong Hort., Fritillaria cirrhosa D.Don, Prunus persica (L.)Batsch, Carthamus tinctorius L., Atractylodes macrocephala Koidz. | HUVECs, exposed to H2O2 (320 μ mol/l) for 6 h | - | - | - | - | Treatment with different concentrations of Buyang Huanwu Decoction | 5,15 and 30 mg/ml | Prevention | pretreated for 6 h | cell viability↑, apoptosis ↓, cleaved Caspase-3↓, ROS↓, MDA↓, SOD↑,MMP↑ | Shen et al. (2016) |
| Guhong injection | Aceglutamide, Carthamus tinctorius L. | Rat Brain Microvascular Endothelial Cells,OGD(1%O2,5% CO2, and 94%N2,6 h)/R (at normal conditions,6 h) | - | - | - | - | treated with different concentrations of Guhong injection | 25,50 and 100 μ l/ml | Prevention | before culture under OGD for 6 h | apoptosis rate↓, MMP↓,Cyt-c↓, LDH↓,MMP-9↓, SOD↑, MDA ↓,p-Akt↑,Bax/Bcl-2↑, cleaved Caspase-3↓, Caspase-3↓ | Zhou et al. (2021a) |
| Guhong injection | Aceglutamide, Carthamus tinctorius L. | - | SD rat | Male | 280 ± 10 g | tMCAO (1 h)/R (7 days) | intraperitoneal injection | 2.5, 5 and 10 ml/kg | treatment | after MCAO, bid for 7 days. | infarct Volume ↓, cleaved Caspase-3↓, Bcl-2/Bax↑, Cyt-c ↓ | Zhou et al. (2021a) |
| YiQiFuMai powder injection | Panax ginseng C. A. Mey., Ophiopogon japonicus (L.f)Ker-Gawl., Schisandra chinensis (Turcz.)Baill. | Primary Cortical Neurons, exposed to H2O2(100 μ M)for 12 h | - | - | - | - | Treated with YiQiFuMai powder injection | 25–800 μ g/ml | Prevention | pretreated for 6 h | Caspase-3↑, cleaved Caspase-3↑,ROS↓, ATP↑,MMP↑,Bcl-2 ↓, Bcl-xl↓, Bax↓,Drp1↓ | Xu et al. (2017) |
| YiQiFuMai powder injection | Panax ginseng C. A. Mey., Ophiopogon japonicus (L.f)Ker-Gawl., Schisandra chinensis (Turcz.)Baill. | - | SD rat | Male | 280–300 g | tMCAO (90min)/R (24 h) | intraperitoneal injection | 0.957 g/kg | treatment | after 90 min of ischemia | Bcl-2↑, Bax↓, cleaved Caspase-9↓, Drp1↓ | Xu et al. (2017) |
| Xingxiong injection | Ginkgo biloba L. extract, tetramethylpyrazine sodium chloride | Primary cortical neurons,OGD(5% CO2 and 95% N2, 2 h)/R (at normal conditions,24 h) | - | - | - | - | treated with Xingxiong injection | 1, 2 and 4 μL/mL | Prevention | before the OGD | Caspase-3 ↓NOX↓, 4-HNE↓,8-OHdG↓ | Zhu et al. (2022) |
| Naoxintong Capsule Combined with Guhong Injection | Aceglutamide, Carthamus tinctorius L., Astragalus membranaceus (Fisch.)Bge., Salvia miltiorrhiza Bge., Paeonia lactiflora Pall., et al. | rBMEC,OGD(1%O2,5% CO2, and 94%N2,4 h)/R (at normal conditions,6 h) | - | - | - | - | treated with Drug-contained rat sera | 12.5,25 and 50 ml/kg, for 14 days | Prevention | At the start of OGD | MDA↓,SOD↑, The apoptotic and necrotic cells↓, MMP↑ | Wang et al. (2021a) |
| The Zhenbao pill | Pteria martensii (Dunker), Cassia obtusifolia L., Bos taurus domesticus Gmelin, Cervus elaphus Linnaeus, Saiga tatarica Linnaeus, Glycyrrhiza uralensis Fisch., et al. | HUVECs, exposed to H2O2(500 μM) for 2 h | - | - | - | - | treated with 10% Drug-contained rat sera | 0.25,0.5 and 1 g/kg, for 7 days | Prevention | pretreated for 12 h | cell viability↑, LDH↓, apoptosis↓,ROS↓,MMP↑,AKT↑,mTOR↑, cell autophagy↓, cell apoptosis↓,Bcl2↑,Beclin1↓,BAX↓, cleaved LC3 II ↓ | Jia et al. (2021) |
| Ershi-wei Chenxiang pills | Aquilaria sinensis (Lour.) Gilg, Ewgewia caryophyllata Thunb., Chaenomeles speciose (Sweet) Nakai, Myristica fragrans Houtt., Carthamus tinctorius L., Choerospondias axillaris (Roxb.) Burtt et Hill, Inula recemosa Hook. f., travertine, Cervus elaphus Linnaeus, Boswellia carterii Birdw., Hyriopsis cumingii (Lea), Aucklandia lappa Decne., Strychnos nux-vomica L., Terminalia chebula Retz., Lagotis brachystachya Maxim., Gossampinus malabarica (DC.) Merr., Phyllanthus emblica L., Dalbergia odorifera T. Chen, Lepus oiostolus Hodgson, and Bos Taurus domesticus Gmelin. | - | SD rat | Male | 260–300 g | MCAO (2 h)/R (24 h) | take orally | 1.33 and 2.00 g/kg | Prevention | pretreated for 14 days,qd | cell viability↑, neuronal apoptosis ↓, Bcl-2↑, Bax↓, Caspase-3↓, Cyt-c↓, CaMK Ⅱ↓, ATF4 ↓,c-Jun↓ | Hou et al. (2020) |
| Pien-Tze-Huang | taurine, malic acid, citric acid, notoginsenoside R1, ginsenosides Rg1, Rb1, Re, Rf, Rd, Rg2, Rg3, Rh1, muscone, cholic acid, hyodeoxycholic acid, taurocholic acid, ursodeoxycholic acid, chenodeoxycholic acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid, glycodeoxycholic acid, and glycocholic acid. | - | SD rat | Male | 240 ± 20 g | MCAO (1.5 h)/R (24 h) | take orally | 180 mg/kg | Prevention | pretreated for 4 days,qd | IL-1β↓,IL-6↓,TNF-α↓, neuronal apoptosis↓, p-AKT↑, p-GSK-3β↑,mitochondrial Cyt-c↑, Cytosolic Cyt-c↓, cleaved Caspase-3↓, cleaved Caspase-9↓, Bax↓, Bcl-xl↑, P53↓ | Zhang et al. (2018b) |
| Xiao-Xu-Ming decoction | Ephedra sinica Stapf, Cassia obtusifolia L., Paeonia lactiflora Pall., Ligusticum chuanxiong Hort., Panax ginseng C. A. Mey., Cnidium monnieri (L.)Cuss., Scutellaria baicalensis Georgi, Dioscorea opposita Thunb., Lindera aggregate (Sims)Kos-term., Aconitum kusnezoffii Reichb., Glycyrrhiza uralensis Fisch., Saposhnikovia divaricata (Turcz.)Schischk., Coptis chinensis Franchet. | - | SD | Male | 250–280 g | MCAO (90 min)/R (24 h) | take orally | 60 g/kg | Prevention | pretreated for 3 days,tid | apoptosis↓,p53↓,Bcl-2↑,Bax↓, Cyt-c↓, Smac/Diablo↓, cytoplasmic c-IAP1↑, Caspase-9↓, Caspase-3↓, Nissl vesicles↑, TUNEL-positive cells↓, Beclin1↑, LC3-I ↑,PINK1↑,Parkin↑ | Lan et al. (2014) |
| Taohong Siwu Decoction | Prunus persica (L.) Batsch, Carthamus tinctorius L., Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Angelica sinensis (Oliv.) Diels, Ligusticum chuanxiong Hort. | - | SD rat | Male | 220–270 g | MCAO (2 h)/R (7 days) | Intraperitoneal injection | 9 g/kg | treatment | after MCAO, qd for 7 days | ROS↓, NLRP3↓, cleaved caspase 1↓, IL-1β↓,IL18↓ | Ji et al. (2022) |
| Bao Yuan Capsule | Cordyceps sinensis (BerK.)Sacc., Astragalus membranaceus (Fisch.)Bge.var.mongholicus (Bge.)Hsiao, Panax ginseng C. A. Mey., Panax notoginseng (Burk.) F. H. Chen | - | C57BL/6 N mice | Male | 20–25 g | MCAO (1.5 h)/R (24days) | Intragastrical administration | 1,2,4 g/kg | treatment | Start on day 3 after MCAO, for 21 days | BrdU+/NeuN+↑,BrdU+/DCX↑, p-Akt↑,p-GSK-3β↑, AMPK↑,β-catenin↓, ACO2↑,SDHA↑ | |
| Bao Yuan Capsule | Cordyceps sinensis (BerK.)Sacc., Astragalus membranaceus (Fisch.)Bge.var.mongholicus (Bge.)Hsiao, Panax ginseng C. A. Mey., Panax notoginseng (Burk.) F. H. Chen | C17.2 cells,OGD(5% CO2 and 95% N2,2 h)/R (at normal conditions,2 or 48 h) | - | - | - | - | treated with Bao Yuan Capsule | 200 μg/ml | treatment | treat for 48 h | ATP↑,AMP↑,ADP↓,ATP/ADP↑, DCX positive↑ | |
| Danhong injection | Salvia miltiorrhiza Bge., Carthamus tinctorius L. | - | SD rat | Male | 260 ± 20 g | MCAO (60 min)/R (7 days) | intravenous injection | 0.5,1.0 and 2.0 mL/kg | treatment | after MCAO, qd for 7days | Inhibits apoptosis↓, SOD↑,T-AOC↑, γH2AX↓,PARP1↓, AIF in nuclear↓, HSP70↑, NAD +↑, pyruvate↑,HIF1α↓, PDK1↓, pPDHA1 ↓, CoA ↑, ATP ↑, ATP-dependent Na+ -K+-ATPase↑ | Zeng et al. (2021b) |
| Huang-Lian-Jie-Du-Decoction | Coptis chinensis Franch., Scutellaria baicalensis Georgi, Phellodendron chinense Schneid., Gardenia jasminoides Ellis | - | SD rat | Male | 280 ± 20 g | MCAO (2 h)/R (24 h) | intragastric administration | 5 g/kg | treatment | after MCAO, qd for 10 days | infarct area↓, the metabolic disturbance↓ | Wang et al. (2014a) |
| Danhong injection | Salvia miltiorrhiza Bge., Carthamus tinctorius L. | Primary cortical neurons, OGD(5% CO2 and 95% N2, 2 h)/R (at normal conditions,4 h) | - | - | - | - | Treated with Danhong injection | 0.75,1.5,3.0 mL/kg | Prevention | incubated the cells for 20 min with Danhong injection | mitochondrial reductase activity ↑ | Orgah et al. (2019) |
| Danhong injection | Salvia miltiorrhiza Bge., Carthamus tinctorius L. | - | SD rat | Male | 250–300 g | MCAO/R | intravenous injection | 0.75,1.5 and 3.0 mL/kg | treatment | After MCAO, bid for 14 days | parkin ↑ | Orgah et al. (2019) |
| Qing Nao Yi Zhi Fang | taurine, malic acid, citric acid, notoginsenoside R1, ginsenosides Rg1, Rb1,Re,Rf,Rd,Rg2,Rg3, Rh1, muscone, cholic acid, hyodeoxycholic acid, taurocholic acid, ursodeoxycholic acid, chenodeoxycholic acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid, glycodeoxycholic acid, and glycocholic acid | neuronal cells, exposed to glutamate,72 h | - | - | - | - | treated with Drug-contained rat sera | 50 μl/ml drug-serum | treatment | After 72 h | ChE ↑, SOD ↑, NO↓, LDH↓, SDH ↑, MMP ↑,ATP↑,apoptosis↓ | Zhang et al. (2000) |
| Naoxintong capsule | Astragalusmembranaceus (Fisch.)Bge.var.mongholicus (Bge.)Hsiao, Paeonia lactiflora Pall., Salvia miltiorrhiza Bge, Angelica sinensis (Oliv.) Diels, Ligusticum chuanxiong Hort., Prunus persica (L.) Batsch, Carthamus tinctorius L., Boswellia carterii Birdw., Commiphora myrrha Engl., Spatholobus suberectus Dunn, Achyranthes bidentata Bl., Cinnamomum cassia Presl, Morus alba L., Pheretima aspergillum (E.Perrier), Buthus martensii Karsch, Hirudo nipponica Whitman | Primary Cortical Neurons, OGD(5% CO2 and 95% N2, 4 h)/R (at normal conditions,2 h) | - | - | - | - | treated with Cerebrospinal fluid containing Naoxintong capsule (BNC) | (2.5%, 5%, and 10%) BNC, Containing Naoxintong capsule | treatment | At the start of OGD, for 4 h | cell viability↑, apoptosis ↓, Ca2+↓, ROS↓,NO↓,nNOS↓, mPTP Opening↓, Cyt-c↓, MMP↓, Bcl-2↑, Bax↓, Caspase-3↓, Caspase-9 ↓, p-Akt↑ | Ma et al. (2016) |
| Shuxuetong injection | Hirudo nipponica Whitman, Pheretima aspergillum (E.Perrier) | bEnd.3, OGD(5% CO2 and 95% N2, 6 h)/R (95% air and 5% CO2, 18 h) | - | - | - | - | treated with Shuxuetong injection | The effective concentration of Shuxuetong injection was separately diluted 32-, 64-, and 128-times | treatment | added to cells during OGD/R | cell viability↑, dehydrogenase leakage↓, cleaved Caspase-3↓,Bcl-2↑,mitochondrial superoxide production↓, oxygen species↓,TNF-α↓,IL-6↓, NF-κB p65 ↓, p-IκBα ↓,IL-1β↓,p-IKK↓, inducible nitric oxide synthase↓, claudin-5↑ | Sun et al. (2019) |
| Mu-Xiang-You-Fang | Aucklandia lappa Decne, Piper nigrum L, Euphorbia pekinensis Rupr, Callorhinusursins Linnaeus, Asarum heterotropoides Fr.Schmidt Var. mandshuricum (Maxim.) Kitag | PC12 cells, OGD(5% CO2 and 95% N2, 2 h)/R (5% CO2 and 95%O2,24 h) | - | - | - | - | treated with Mu-Xiang-You-Fang | 1, 2, 4 μg/mL | treatment | after MCAO | LDH ↓,MMP↑, Ca2+↓, survival rate↑,autophagy↓, LC3 ↓,p62↑, beclin1 ↓, p-AMPK↓, ULK1↓, p-mTOR↑, p-p70s6k↑ | Ma et al. (2020) |
| Tong Luo Jiu Nao injection | Panax notoginseng (Burk.) F.H.Chen, Gardenia jasminoides Ellis | BMECs,OGD(7% CO2 and 93% N2, 6 h)/R (at normal conditions,10 h) | - | - | - | - | treated with Tong Luo Jiu Nao injection | 2 μl/ml | treatment | after MCAO | LDH↓, Ca2+↓, NMDAR1↓,MMP↑,Cyt-c↓, VEGF↑, PAF↓ | Li et al. (2014) |
| ANNAO tablets | Not mentioned | - | SD rat | Male | 250–270 g | MCAO (2 h)/R (1 or 7 days) | Intragastrical administration | 300,600 and 1,200 mg/kg | treatment | 1 h after the start of reperfusion, qd for 1 day or 7 days | infarct volumes ↓, PINK1↑, Parkin↑, Drp1↑, Cyt-c↓,Bcl-2/Bax↑, NeuN-positive neuron↑ | Zhang et al. (2020b) |
| Gualou Guizhi Decoction | Trichosanthes kirilowii Maxim., Cinnamomum cassia Presl., Paeoniae lactiflora Pall., Zingiber officinale Rosc., Ziziphus jujuba Mill., Glycyrrhiza uralensis Fisch. | - | SD rat | Male | 210–230 g | MCAO (2 h)/R (7days) | Intragastrical administration | 3.6 g/kg,7.2 g/kg and14.4 g/kg | treatment | after MCAO, qd for 7 days | Nissl-Positive Cells↑,PARP-1↓, AIF↓, Endo G↓, Hsp70↑, nucleus PARP-1↓, nucleus AIF ↓, nucleus Endo G↓, mitochondria AIF↑, mitochondria Endo G↑ | Nan et al. (2020) |
| Danhong Injection | Salvia miltiorrhiza Bge., Carthamus tinctorius L. | - | SD rat | Male | 260–290 g | MCAO/R | Intravenous Injections | 0.84 mL/kg | treatment | after MCAO, qd for 3 days. | Apoptosis↓, Cyt-c↓,MDM2↓,p-Akt↑, Bim↓,p53↓ | |
| Huang-Lian-Jie-Du Decoction | Coptis chinensis Franch., Scutellaria baicalensis Georgi, Phellodendron chinense Schneid., Gardenia jasminoides Ellis | - | SD rat | Male | 200–220 g | MCAO (1.5 h)/R (24 h) | Intraperitoneal Injections | Baicalin (5 mg/ml),jasminoidin (25 mg/ml) | treatment | After reperfusion | Bak↓ | Wang et al. (2019b) |
The molecular mechanism of TCM prescription in the treatment of ischemic stroke by targeting mitochondria.
Notes: ↑, upregulate; ↓, downregulate; SD, Sprague-Dawley; MCAO/R, middle cerebral artery occlusion/reperfusion; bid, two times a day; LC3B, light chain 3B; VDAC1,voltage-dependent anion channel 1; Lamp1, Lysosome-associated membrane protein 1; HUVEC, human umbilical vein endothelial cells; H2O2, hydrogen peroxide; Caspase, cysteinyl aspartate specific proteinase; MMP-9, matrix metalloproteinase-9; LDH, lactate dehydrogenase; tMCAO, transient middle cerebral artery occlusion; NOX, NADPH, oxidases; 4-HNE, 4-Hydroxynonena; 8-OHdG,8-Hydroxydeoxyguanosine; rBMEC, brain microvessel endothelial cells; LC3-Ⅱ, Light chain 3Ⅱ; qd, once a day; CaMK Ⅱ, calmodulin-dependent protein kinase II; ATF4, Activating Transcription Factor 4; IL-1β, Interleukin-1, beta; IL-6, Interleukin-6; TNF-α, tumor necrosis factor-α; p-GSK-3β, phosphonated glycogen synthase kinase-3β; p53, protein 53; tid, three time a day; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling; LC3-I, Light chain 3 I; PINK1, PTEN, induced putative kinase 1; NLRP3, Nod-like receptor protein 3; IL18, Interleukin-18; BrdU+, 5-Bromodeoxyuridinc; DCX, doublecortin; ACO2, aminocyclopropanecarboxylate oxidase; SDHA, Succinate Dehydrogenase Complex Flavoprotein Subunit A; AMP, adenosine monophosphate; ADP, adenosine vdiphosphate; DCX, doublecortin; C17.2 cells, C17.2 mouse neural stem cells; T-AOC, total antioxidant capacity; PARP1, poly ADP-ribose polymerase 1; HSP70, Heat shock 70 kDa protein; NAD, nicotinamide adenine dinucleotide; CoA, coenzyme A; ChE, choline esterase; NO, nitric oxide; SDH, succinate dehydrogenase; nNOS, neuronal nitric oxide synthase; NF-κB, Nuclear factor kappa-B; p-IKK, phosphonated Inhibitor of kappa B kinase; LC3, light chain 3; p-AMPK, Phosphorylation of AMP-activated protein kinase; P-mTOR, phosphorylation of mammalian target of rapamycin; p-p70s6k, Phosphorylation of p70 ribosomal protein S6 kinase; NMDAR1, N-methyl-D-aspartic acid receptor1; VEGF, vascular endothelial growth factor; PAF, Platelet-activating factor; Drp1, Dynamin-related protein 1; MDM2, murine double minute2; p-IκBα, phosphonated inhibitor of nuclear factor kappaB; ULK1, Unc-51-like kinase 1; γH2AX, gamma H2A histone family member X; pPDHA1, phosphonated Pyruvate Dehydrogenase E1 Subunit Alpha 1.
3.5 The specific molecular mechanism among acupuncture, herbal extracts, TCM compounds, and TCM prescriptions in treating ischemic stroke
Acupuncture, herbal medicine, TCM compounds, and TCM prescriptions prevent and treat ischemic stroke by improving abnormal mitochondrial structure, increasing MMP levels, mitochondrial respiration function, and mitochondrial energy metabolism, decreasing oxidative stress, maintaining mitochondrial fission and fusion dynamics, promoting mitochondrial biogenesis, regulating mitophagy, and inhibiting mitochondrial-dependent apoptosis. However, the specific molecular mechanism differs among acupuncture, herbal extracts, TCM compounds, and TCM prescriptions in treating ischemic stroke. Acupuncture, herbal extract, TCM compounds, and TCM prescriptions could alleviate mitochondrial respiration function and energy metabolism by improving the electron transport chain. Acupuncture, TCM compounds, and TCM prescriptions can improve tricarboxylic acid cycle dysfunction. Additionally, TCM compounds and TCM prescriptions can improve mitochondrial respiration and energy metabolism by inhibiting the hypoxia-inducible factor 1-alpha/pyruvate dehydrogenase kinase 1(HIF1α/PDK1) pathway. Acupuncture inhibited mitochondrial fission, whereas herbal extracts and TCM prescriptions promoted mitochondrial fusion. However, the results regarding mitochondrial fission have been inconsistent in studies of herbal extracts, TCM compounds, and TCM prescriptions. We noted that TCM compounds decreased Drp1 translocation from the cytosol to the outer mitochondrial membrane by inhibiting Jak2/Stat3. In contrast, TCM prescriptions decreased Drp1 translocation from the cytosol to the outer mitochondrial membrane by inhibiting PKCδ. Acupuncture, TCM compounds, and TCM prescriptions promoted mitophagy by activating the PINK1/Parkin pathway. On the other hand, herbal extracts, TCM compounds, and TCM prescriptions suppressed mitophagy by inhibiting the AMPK/mTOR pathway.
Acupuncture could attenuate mitophagy by inhibiting the p-ULK1/FUNDC1 pathway, whereas TCM compounds could inhibit mitophagy by activating the PI3k/Akt pathway. Acupuncture, herbal extracts, TCM compounds, and TCM prescriptions can upregulate the expression of anti-apoptotic proteins in the BCL-2 family and downregulate the expression of pro-apoptotic proteins in the BCL-2 family. In addition, acupuncture prevented Smac/DIABLO and cofilin translocation from the mitochondria into the cytoplasm, whereas TCM compounds inhibited Endo G and AIF release from the mitochondria into the cytoplasm. Moreover, TCM prescriptions could inhibit Smac/DIABLO, Endo G, and AIF release from the mitochondria into the cytoplasm. Generally, the above evidence demonstrated that the specific molecular mechanism differed among acupuncture, herbal extract, TCM compounds, and TCM prescriptions in treating ischemic stroke (Figures 1, 3).
Interestingly, only TCM compounds have been reported to promote the transfer of astrocytic mitochondria to neurons in response to ischemic stroke. Emerging evidence suggests that mitochondria could serve as “help-me” signaling in response to various external stimuli and recruit neighboring cells to rescue injured cells. Removing damaged mitochondria and replacing them with healthy ones is a potential treatment for hypoxia and ischemia-related disorders, especially in the central nervous system, where mitochondria are abundant in the distal axonal synapses and dendritic protrusions. More studies can be conducted exploring the underlying therapeutic mechanism of TCM in treating ischemic stroke from the perspective of mitochondrial transfer.
4 Conclusion and prospects
In this review, we summarize the molecular mechanisms underlying the involvement of mitochondria in ischemic stroke. Mitochondrial function and structure play important roles in ischemic stroke, serving as crucial targets for TCM in alleviating ischemic stroke, and we have identified some key proteins and signaling pathways, as mentioned above. In addition, some issues require further clarification and improvement in future research. First, the precise molecular mechanisms underlying the effects of TCM on mitochondria in cellular and rat models of ischemic stroke remain incompletely understood. Further research is needed to elucidate the underlying mechanisms of TCM’s effects on mitochondrial structure and function in ischemic stroke, using molecular, cellular, and biochemical approaches. Second, the lack of standardized experimental designs and methods may affect the reproducibility and comparability of the results. Standardization of experimental designs and methods, including the quality control of TCM preparations, should be established to ensure the scientific rigor and reliability of future studies. Third, in the field of EA therapy for ischemic stroke, research from the perspective of mitochondria is scarce in comparison to studies on herbal extracts, compounds, and prescriptions. More rigorous and well-designed studies are urgently needed. In addition, it is critical to establish standardized EA stimulation parameters (e.g., frequency, duration, and intensity) to investigate the dose-response relationship and corresponding mechanisms from the perspective of mitochondria in future studies. Fourth, the results of mitophagy, mitochondrial fission, and mitochondrial fusion have been inconsistent among studies. These controversial results might be associated with different experimental models, different stages of ischemic stroke, and intervention modes. Further investigations are required to elucidate this. Fifth, most of the studies summarized above are based on OGD/R or MCAO ischemia models, and most MCAO ischemia models are conducted on young rats or mice. Few studies have used aged animals or models that closely mimic clinical patients who often have hypertension, hyperglycemia, or other disorders. Therefore, it is necessary to investigate the neuroprotective benefits of TCM against ischemic stroke using pseudo-clinical models (e.g., complicated models of multiple coexisting disorders), which will provide a reliable foundation for TCM’s clinical application of TCM. Sixth, most in vitro studies mentioned above were limited to a particular type of nerve cells. Neurovascular dysfunction induced by ischemic stroke demonstrates a combined action of multiple nerves in the brain, and investigating only one type of nerve cell is insufficient. Thus, ischemic stroke can be better understood using a cell co-culture model of neurons, microglia, and astrocytes in vitro. Finally, since Chinese herbs and prescriptions contain various chemical components, the precise underlying mechanisms remain unknown. Further research is required into the molecular targets and active components that contribute to the bioactivity of Chinese herbs and prescriptions in preventing and treating ischemic stroke. Furthermore, we should examine the synergic effects of the constituents and their metabolites, as well as the targeted signaling pathways in post-ischemic brains.
In conclusion, this review summarizes the recent experimental evidence of TCM in preventing and treating ischemic stroke by modulating mitochondria and identifies areas that future research should focus on. In addition, TCM has few side effects and is highly effective and specific; therefore, with adequate research, it will be widely available for ischemic stroke treatment.
Statements
Author contributions
LL conceived the study. LL, DC, ZZ, JY, MS,YC, MZ, YL,SS and JC reviewed and summarized the literatures. LL wrote the manuscript and drew all the figures. DC, ZZ and JC created the tables. LZ and JC supervised and revised the study and gave final approval of the version to be published. The final version of the manuscript was read and approved by all authors.
Funding
This study was supported by the National Natural Science Foundation of China (Grant No. 82274664), Department of Science and Technology of Sichuan Province (2023NSFSC1822), Sichuan Provincial central guiding local science and technology development special project (Grant No. 2021ZYD0103), and Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (Grant No. ZYYCXTD-D-202003).
Acknowledgments
We acknowledge the assistance of Editage (www.editage.cn) for their professional editing services, which have significantly improved the English language quality of our manuscript. Moreover, we would like to extend our appreciation to Biorender for their essential role in the creation of Figure 1, Figure 2, Figure 3, Figure 4, and Figure 5.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Glossary
- ATP
adenosine triphosphate
- TCM
traditional Chinese medicine
- OGD
oxygen-glucose deprivation
- ROS
reactive oxygen species
- tPA
tissue plasminogen activator
- mPTP
mitochondrial permeability transition pore
- MMP
mitochondrial membrane potential
- NAD+
nicotinamide adenine dinucleotide
- MAMs
mitochondria-associated endoplasmic reticulum membranes
- I/R
ischemia/reperfusion
- OGD/R
oxygen-glucose deprivation/reoxygenation
- mtDNA
mitochondrial DNA
- PGC-1α
peroxisome proliferator-activated receptor γ coactivator-1α
- AMPK
AMP-activated protein kinase
- SIRT1
phosphorylation and sirtuin 1
- NRF1/2
nuclear respiratory factors 1/2
- TFAM
mitochondrial transcription factor A
- Drp1
dynamin-related protein 1
- Mfn1/2
mitofusins-1/mitofusins-2
- Opa1
optic atrophy 1
- BNIP3
Bcl-2/E1B-19 KD-interacting protein 3
- FUNDC1
FUN14 domain containing 1
- MCAO
middle cerebral artery occlusion
- Endo G
endonuclease G
- Apaf-1
apoptosis activating factor-1
- IAPs
inhibitor-of-apoptosis proteins
- AIF
apoptosis-related proteins
- EA
electroacupuncture
- MDA
malondialdehyde
- SOD
superoxide dismutase
- mTOR
mammalian target of rapamycin
- Smac/Diablo
the second mitochondrion-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI
- Cyto-Cyt-c
Cyt-c in the cytoplasm
- Mito-Cyt-c
mitochondrial Cyt-c
- cIAP-1
-2, cellular inhibitor of apoptosis- 1,-2
- XIAP
X-linked inhibitor of apoptosis protein
- p-Bad
phospho-Bad
- BNIP3L
NIP3-like protein X
- Cyt-c
cytochrome C
- HIF1α/PDK1
hypoxia-inducible factor 1-alpha/pyruvate dehydrogenase kinase 1
- ROS
reactive oxygen species
References
1
AderN. R.HoffmannP. C.GanevaI.BorgeaudA. C.WangC.YouleR. J.et al (2019). Molecular and topological reorganizations in mitochondrial architecture interplay during Bax-mediated steps of apoptosis. Elife8, e40712. 10.7554/eLife.40712
2
AjoolabadyA.WangS.KroemerG.PenningerJ. M.UverskyV. N.PraticoD.et al (2021). Targeting autophagy in ischemic stroke: From molecular mechanisms to clinical therapeutics. Pharmacol. Ther.225, 107848. 10.1016/j.pharmthera.2021.107848
3
AlkahtaniS.Al-JohaniN. S.AlarifiS. (2023). Mechanistic insights, treatment paradigms, and clinical progress in neurological disorders: Current and future prospects. Int. J. Mol. Sci.24 (2), 1340. 10.3390/ijms24021340
4
AnH.TaoW.LiangY.LiP.LiM.ZhangX.et al (2021). Dengzhanxixin injection ameliorates cognitive impairment through a neuroprotective mechanism based on mitochondrial preservation in patients with acute ischemic stroke. Front. Pharmacol.12, 712436. 10.3389/fphar.2021.712436
5
AndrabiS. S.ParvezS.TabassumH. (2020). Ischemic stroke and mitochondria: Mechanisms and targets. Protoplasma257 (2), 335–343. 10.1007/s00709-019-01439-2
6
AnzellA. R.MaizyR.PrzyklenkK.SandersonT. H. (2018). Mitochondrial quality control and disease: Insights into ischemia-reperfusion injury. Mol. Neurobiol.55 (3), 2547–2564. 10.1007/s12035-017-0503-9
7
BaiX.TanT. Y.LiY. X.LiY.ChenY. F.MaR.et al (2020). The protective effect of cordyceps sinensis extract on cerebral ischemic injury via modulating the mitochondrial respiratory chain and inhibiting the mitochondrial apoptotic pathway. Biomed. Pharmacother.124, 109834. 10.1016/j.biopha.2020.109834
8
CenJ.ZhangR.ZhaoT.ZhangX.ZhangC.CuiJ.et al (2022). A water-soluble quercetin conjugate with triple targeting exerts neuron-protective effect on cerebral ischemia by mitophagy activation. Adv. Healthc. Mater11 (22), e2200817. 10.1002/adhm.202200817
9
ChenA.WangH.ZhangY.WangX.YuL.XuW.et al (2017). Paeoniflorin exerts neuroprotective effects against glutamate-induced PC12 cellular cytotoxicity by inhibiting apoptosis. Int. J. Mol. Med.40 (3), 825–833. 10.3892/ijmm.2017.3076
10
ChenB.LinW. Q.LiZ. F.ZhongX. Y.WangJ.YouX. F.et al (2021). Electroacupuncture attenuates ischemic brain injury and cellular apoptosis via mitochondrial translocation of cofilin. Chin. J. Integr. Med.27 (9), 705–712. 10.1007/s11655-021-3335-4
11
ChenS. D.YangD. I.LinT. K.ShawF. Z.LiouC. W.ChuangY. C. (2011). Roles of oxidative stress, apoptosis, PGC-1α and mitochondrial biogenesis in cerebral ischemia. Int. J. Mol. Sci.12 (10), 7199–7215. 10.3390/ijms12107199
12
ChenS.SunM.ZhaoX.YangZ.LiuW.CaoJ.et al (2019). Neuroprotection of hydroxysafflor yellow A in experimental cerebral ischemia/reperfusion injury via metabolic inhibition of phenylalanine and mitochondrial biogenesis. Mol. Med. Rep.19 (4), 3009–3020. 10.3892/mmr.2019.9959
13
ChengC. Y.HoT. Y.HsiangC. Y.TangN. Y.HsiehC. L.KaoS. T.et al (2017). Angelica sinensis exerts angiogenic and anti-apoptotic effects against cerebral ischemia-reperfusion injury by activating p38MAPK/HIF-1[Formula: See text]/VEGF-A signaling in rats. Am. J. Chin. Med.45 (8), 1683–1708. 10.1142/s0192415x17500914
14
ChengC. Y.KaoS. T.LeeY. C. (2019). Ferulic acid ameliorates cerebral infarction by activating Akt/mTOR/4E-BP1/Bcl-2 anti-apoptotic signaling in the penumbral cortex following permanent cerebral ischemia in rats. Mol. Med. Rep.19 (2), 792–804. 10.3892/mmr.2018.9737
15
ChengC. Y.LinJ. G.TangN. Y.KaoS. T.HsiehC. L. (2015). Electroacupuncture at different frequencies (5Hz and 25Hz) ameliorates cerebral ischemia-reperfusion injury in rats: Possible involvement of p38 MAPK-mediated anti-apoptotic signaling pathways. BMC Complement. Altern. Med.15, 241. 10.1186/s12906-015-0752-y
16
CohenM. M.TaresteD. (2018). Recent insights into the structure and function of Mitofusins in mitochondrial fusion. F1000Res7, F1000. 10.12688/f1000research.16629.1
17
CuiW. H.ZhangH. H.QuZ. M.WangZ.ZhangD. J.WangS. (2022). Effects of chrysophanol on hippocampal damage and mitochondrial autophagy in mice with cerebral ischemia reperfusion. Int. J. Neurosci.132 (6), 613–620. 10.1080/00207454.2020.1830085
18
DohareP.GargP.SharmaU.JagannathanN. R.RayM. (2008a). Neuroprotective efficacy and therapeutic window of curcuma oil: In rat embolic stroke model. BMC Complement. Altern. Med.8, 55. 10.1186/1472-6882-8-55
19
DohareP.VarmaS.RayM. (2008b). Curcuma oil modulates the nitric oxide system response to cerebral ischemia/reperfusion injury. Nitric Oxide19 (1), 1–11. 10.1016/j.niox.2008.04.020
20
DuQ.DengR.LiW.ZhangD.TsoiB.ShenJ. (2021). Baoyuan Capsule promotes neurogenesis and neurological functional recovery through improving mitochondrial function and modulating PI3K/Akt signaling pathway. Phytomedicine93, 153795. 10.1016/j.phymed.2021.153795
21
EnginA.EnginA. B. (2021). N-Methyl-D-Aspartate receptor signaling-protein kinases crosstalk in cerebral ischemia. Adv. Exp. Med. Biol.1275, 259–283. 10.1007/978-3-030-49844-3_10
22
FengC.WanH.ZhangY.YuL.ShaoC.HeY.et al (2020). Neuroprotective effect of Danhong injection on cerebral ischemia-reperfusion injury in rats by activation of the PI3K-Akt pathway. Front. Pharmacol.11, 298. 10.3389/fphar.2020.00298
23
FengL.GaoJ.LiuY.ShiJ.GongQ. (2018). Icariside II alleviates oxygen-glucose deprivation and reoxygenation-induced PC12 cell oxidative injury by activating Nrf2/SIRT3 signaling pathway. Biomed. Pharmacother.103, 9–17. 10.1016/j.biopha.2018.04.005
24
GiorgiC.MarchiS.SimoesI. C. M.RenZ.MorcianoG.PerroneM.et al (2018). Mitochondria and reactive oxygen species in aging and age-related diseases. Int. Rev. Cell. Mol. Biol.340, 209–344. 10.1016/bs.ircmb.2018.05.006
25
GuidaM.ZanonA.MontibellerL.LavdasA. A.LadurnerJ.PischeddaF.et al (2019). Parkin interacts with apoptosis-inducing factor and interferes with its translocation to the nucleus in neuronal cells. Int. J. Mol. Sci.20 (3), 748. 10.3390/ijms20030748
26
GuoC.MaY. Y. (2021). Calcium permeable-AMPA receptors and excitotoxicity in neurological disorders. Front. Neural Circuits15, 711564. 10.3389/fncir.2021.711564
27
HeJ.LiuJ.HuangY.ZhuoY.ChenW.DuanD.et al (2020a). Olfactory mucosa mesenchymal stem cells alleviate cerebral ischemia/reperfusion injury via golgi apparatus secretory pathway Ca(2+) -ATPase Isoform1. Front. Cell. Dev. Biol.8, 586541. 10.3389/fcell.2020.586541
28
HeM.MaY.WangR.ZhangJ.JingL.LiP. A. (2020b). Deletion of mitochondrial uncoupling protein 2 exacerbates mitochondrial damage in mice subjected to cerebral ischemia and reperfusion injury under both normo- and hyperglycemic conditions. Int. J. Biol. Sci.16 (15), 2788–2802. 10.7150/ijbs.48204
29
HouY.QieniX.LiN.BaiJ.LiR.GongbaoD.et al (2020). Longzhibu disease and its therapeutic effects by traditional Tibetan medicine: Ershi-wei Chenxiang pills. J. Ethnopharmacol.249, 112426. 10.1016/j.jep.2019.112426
30
HuJ.ZengC.WeiJ.DuanF.LiuS.ZhaoY.et al (2020). The combination of Panax ginseng and Angelica sinensis alleviates ischemia brain injury by suppressing NLRP3 inflammasome activation and microglial pyroptosis. Phytomedicine76, 153251. 10.1016/j.phymed.2020.153251
31
HuS.HuH.MakS.CuiG.LeeM.ShanL.et al (2018). A novel tetramethylpyrazine derivative prophylactically protects against glutamate-induced excitotoxicity in primary neurons through the blockage of N-Methyl-D-aspartate receptor. Front. Pharmacol.9, 73. 10.3389/fphar.2018.00073
32
HuangP.WuS. P.WangN.SetoS.ChangD. (2021). Hydroxysafflor yellow A alleviates cerebral ischemia reperfusion injury by suppressing apoptosis via mitochondrial permeability transition pore. Phytomedicine85, 153532. 10.1016/j.phymed.2021.153532
33
HuangQ.LouT.WangM.XueL.LuJ.ZhangH.et al (2020). Compound K inhibits autophagy-mediated apoptosis induced by oxygen and glucose deprivation/reperfusion via regulating AMPK-mTOR pathway in neurons. Life Sci.254, 117793. 10.1016/j.lfs.2020.117793
34
HuangX. P.TanH.ChenB. Y.DengC. Q. (2012). Astragalus extract alleviates nerve injury after cerebral ischemia by improving energy metabolism and inhibiting apoptosis. Biol. Pharm. Bull.35 (4), 449–454. 10.1248/bpb.35.449
35
HuangX. P.TanH.ChenB. Y.DengC. Q. (2017). Combination of total Astragalus extract and total Panax notoginseng saponins strengthened the protective effects on brain damage through improving energy metabolism and inhibiting apoptosis after cerebral ischemia-reperfusion in mice. Chin. J. Integr. Med.23 (6), 445–452. 10.1007/s11655-015-1965-0
36
JakicB.CarlssonM.BuszkoM.CappellanoG.PlonerC.OnestingelE.et al (2019). The effects of endurance exercise and diet on atherosclerosis in young and aged ApoE-/- and wild-type mice. Gerontology65 (1), 45–56. 10.1159/000492571
37
JiZ. J.ShiY.LiX.HouR.YangY.LiuZ. Q.et al (2022). Neuroprotective effect of taohong Siwu decoction on cerebral ischemia/reperfusion injury via mitophagy-NLRP3 inflammasome pathway. Front. Pharmacol.13, 910217. 10.3389/fphar.2022.910217
38
JiaY.ChenX.ChenY.LiH.MaX.XingW.et al (2021). Zhenbao pill attenuates hydrogen peroxide-induced apoptosis by inhibiting autophagy in human umbilical vein endothelial cells. J. Ethnopharmacol.274, 114020. 10.1016/j.jep.2021.114020
39
KaarnirantaK.KajdanekJ.MorawiecJ.PawlowskaE.BlasiakJ. (2018). PGC-1α protects RPE cells of the aging retina against oxidative stress-induced degeneration through the regulation of senescence and mitochondrial quality control the significance for AMD pathogenesis. Int. J. Mol. Sci.19 (8), 2317. 10.3390/ijms19082317
40
KaushikP.AliM.SalmanM.TabassumH.ParvezS. (2021). Harnessing the mitochondrial integrity for neuroprotection: Therapeutic role of piperine against experimental ischemic stroke. Neurochem. Int.149, 105138. 10.1016/j.neuint.2021.105138
41
KimY. R.KimH. N.JangJ. Y.ParkC.LeeJ. H.ShinH. K.et al (2013). Effects of electroacupuncture on apoptotic pathways in a rat model of focal cerebral ischemia. Int. J. Mol. Med.32 (6), 1303–1310. 10.3892/ijmm.2013.1511
42
LanR.ZhangY.WuT.MaY. Z.WangB. Q.ZhengH. Z.et al (2018). Xiao-xu-ming decoction reduced mitophagy activation and improved mitochondrial function in cerebral ischemia and reperfusion injury. Behav. Neurol.2018, 4147502. 10.1155/2018/4147502
43
LanR.ZhangY.XiangJ.ZhangW.WangG. H.LiW. W.et al (2014). Xiao-Xu-Ming decoction preserves mitochondrial integrity and reduces apoptosis after focal cerebral ischemia and reperfusion via the mitochondrial p53 pathway. J. Ethnopharmacol.151 (1), 307–316. 10.1016/j.jep.2013.10.042
44
LeiT.LiH.FangZ.LinJ.WangS.XiaoL.et al (2014). Polysaccharides from Angelica sinensis alleviate neuronal cell injury caused by oxidative stress. Neural Regen. Res.9 (3), 260–267. 10.4103/1673-5374.128218
45
LiC.ChenC.QinH.AoC.ChenJ.TanJ.et al (2022a). The role of mitochondrial dynamin in stroke. Oxid. Med. Cell. Longev.2022, 2504798. 10.1155/2022/2504798
46
LiF.TanJ.ZhouF.HuZ.YangB. (2018a). Heat shock protein B8 (HSPB8) reduces oxygen-glucose deprivation/reperfusion injury via the induction of mitophagy. Cell. Physiol. Biochem.48 (4), 1492–1504. 10.1159/000492259
47
LiG.LiX.DongJ.HanY. (2021a). Electroacupuncture ameliorates cerebral ischemic injury by inhibiting ferroptosis. Front. Neurol.12, 619043. 10.3389/fneur.2021.619043
48
LiH.HanW.WangH.DingF.XiaoL.ShiR.et al (2017). Tanshinone IIA inhibits glutamate-induced oxidative toxicity through prevention of mitochondrial dysfunction and suppression of MAPK activation in SH-SY5Y human neuroblastoma cells. Oxid. Med. Cell. Longev.2017, 4517486. 10.1155/2017/4517486
49
LiJ.BuY.LiB.ZhangH.GuoJ.HuJ.et al (2022b). Calenduloside E alleviates cerebral ischemia/reperfusion injury by preserving mitochondrial function. J. Mol. Histol.53 (4), 713–727. 10.1007/s10735-022-10087-5
50
LiJ.ZhaoT.QiaoH.LiY.XiaM.WangX.et al (2022c). Research progress of natural products for the treatment of ischemic stroke. J. Integr. Neurosci.21 (1), 14. 10.31083/j.jin2101014
51
LiS.PengT.ZhaoX.SilvaM.LiuL.ZhouW.et al (2021b). Artemether confers neuroprotection on cerebral ischemic injury through stimulation of the Erk1/2-P90rsk-CREB signaling pathway. Redox Biol.46, 102069. 10.1016/j.redox.2021.102069
52
LiS.WangT.ZhaiL.GeK.ZhaoJ.CongW.et al (2018b). Picroside II exerts a neuroprotective effect by inhibiting mPTP permeability and EndoG release after cerebral ischemia/reperfusion injury in rats. J. Mol. Neurosci.64 (1), 144–155. 10.1007/s12031-017-1012-z
53
LiW. H.YangY. L.ChengX.LiuM.ZhangS. S.WangY. H.et al (2020). Baicalein attenuates caspase-independent cells death via inhibiting PARP-1 activation and AIF nuclear translocation in cerebral ischemia/reperfusion rats. Apoptosis25 (5-6), 354–369. 10.1007/s10495-020-01600-w
54
LiW.LiP.LiuZ.DuQ.SteinmetzA.WangN.et al (2014). A Chinese medicine preparation induces neuroprotection by regulating paracrine signaling of brain microvascular endothelial cells. J. Ethnopharmacol.151 (1), 686–693. 10.1016/j.jep.2013.11.035
55
LiX.ZhangD.BaiY.XiaoJ.JiaoH.HeR. (2019). Ginaton improves neurological function in ischemic stroke rats via inducing autophagy and maintaining mitochondrial homeostasis. Neuropsychiatr. Dis. Treat.15, 1813–1822. 10.2147/ndt.S205612
56
LinG. H.LinL.LiangH. W.MaX.WangJ. Y.WuL. P.et al (2010). Antioxidant action of a Chrysanthemum morifolium extract protects rat brain against ischemia and reperfusion injury. J. Med. Food13 (2), 306–311. 10.1089/jmf.2009.1184
57
LiuB.ZhaoT.LiY.HanY.XuY.YangH.et al (2022). Notoginsenoside R1 ameliorates mitochondrial dysfunction to circumvent neuronal energy failure in acute phase of focal cerebral ischemia. Phytother. Res.36 (5), 2223–2235. 10.1002/ptr.7450
58
LiuQ.LiX.LiL.XuZ.ZhouJ.XiaoW. (2018). Ginkgolide K protects SH-SY5Y cells against oxygen-glucose deprivation-induced injury by inhibiting the p38 and JNK signaling pathways. Mol. Med. Rep.18 (3), 3185–3192. 10.3892/mmr.2018.9305
59
LiuW. J.JiangH. F.RehmanF. U.ZhangJ. W.ChangY.JingL.et al (2017). Lycium barbarum polysaccharides decrease hyperglycemia-aggravated ischemic brain injury through maintaining mitochondrial fission and fusion balance. Int. J. Biol. Sci.13 (7), 901–910. 10.7150/ijbs.18404
60
LuF.WangL.ChenY.ZhongX.HuangZ. (2020). In vitro cultured calculus bovis attenuates cerebral ischaemia-reperfusion injury by inhibiting neuronal apoptosis and protecting mitochondrial function in rats. J. Ethnopharmacol.263, 113168. 10.1016/j.jep.2020.113168
61
LuanY.YangD.ZhangZ.BieX.ZhaoH.WangY.et al (2021). Association study between genetic variation in whole mitochondrial genome and ischemic stroke. J. Mol. Neurosci.71 (10), 2152–2162. 10.1007/s12031-020-01778-3
62
MaH. X.HouF.ChenA. L.LiT. T.ZhuY. F.ZhaoQ. P. (2020). Mu-Xiang-You-Fang protects PC12 cells against OGD/R-induced autophagy via the AMPK/mTOR signaling pathway. J. Ethnopharmacol.252, 112583. 10.1016/j.jep.2020.112583
63
MaY.ZhaoP.ZhuJ.YanC.LiL.ZhangH.et al (2016). Naoxintong protects primary neurons from oxygen-glucose deprivation/reoxygenation induced injury through PI3K-Akt signaling pathway. Evid. Based Complement. Altern. Med.2016, 5815946. 10.1155/2016/5815946
64
MaoC.HuC.ZhouY.ZouR.LiS.CuiY.et al (2020). Electroacupuncture pretreatment against cerebral ischemia/reperfusion injury through mitophagy. Evid. Based Complement. Altern. Med.2020, 7486041. 10.1155/2020/7486041
65
MaoZ.TianL.LiuJ.WuQ.WangN.WangG.et al (2022). Ligustilide ameliorates hippocampal neuronal injury after cerebral ischemia reperfusion through activating PINK1/Parkin-dependent mitophagy. Phytomedicine101, 154111. 10.1016/j.phymed.2022.154111
66
MengX.XieW.XuQ.LiangT.XuX.SunG.et al (2018). Neuroprotective effects of radix scrophulariae on cerebral ischemia and reperfusion injury via MAPK pathways. Molecules23 (9), 2401. 10.3390/molecules23092401
67
MondalN. K.BeheraJ.KellyK. E.GeorgeA. K.TyagiP. K.TyagiN. (2019). Tetrahydrocurcumin epigenetically mitigates mitochondrial dysfunction in brain vasculature during ischemic stroke. Neurochem. Int.122, 120–138. 10.1016/j.neuint.2018.11.015
68
MukherjeeA.SarkarS.JanaS.SwarnakarS.DasN. (2019). Neuro-protective role of nanocapsulated curcumin against cerebral ischemia-reperfusion induced oxidative injury. Brain Res.1704, 164–173. 10.1016/j.brainres.2018.10.016
69
NanL.XieQ.ChenZ.ZhangY.ChenY.LiH.et al (2020). Involvement of PARP-1/AIF signaling pathway in protective effects of Gualou Guizhi decoction against ischemia-reperfusion injury-induced apoptosis. Neurochem. Res.45 (2), 278–294. 10.1007/s11064-019-02912-3
70
NiX. C.WangH. F.CaiY. Y.YangD.AlolgaR. N.LiuB.et al (2022). Ginsenoside Rb1 inhibits astrocyte activation and promotes transfer of astrocytic mitochondria to neurons against ischemic stroke. Redox Biol.54, 102363. 10.1016/j.redox.2022.102363
71
OrgahJ. O.RenJ.LiuX.OrgahE. A.GaoX. M.ZhuY. (2019). Danhong injection facilitates recovery of post-stroke motion deficit via Parkin-enhanced mitochondrial function. Restor. Neurol. Neurosci.37 (4), 375–395. 10.3233/rnn-180828
72
ParkH. R.LeeH.LeeJ. J.YimN. H.GuM. J.MaJ. Y. (2018). Protective effects of spatholobi caulis extract on neuronal damage and focal ischemic stroke/reperfusion injury. Mol. Neurobiol.55 (6), 4650–4666. 10.1007/s12035-017-0652-x
73
PengT.LiS.LiuL.YangC.FarhanM.ChenL.et al (2022). Artemisinin attenuated ischemic stroke induced cell apoptosis through activation of ERK1/2/CREB/BCL-2 signaling pathway in vitro and in vivo. Int. J. Biol. Sci.18 (11), 4578–4594. 10.7150/ijbs.69892
74
QuintanaD. D.GarciaJ. A.SarkarS. N.JunS.Engler-ChiurazziE. B.RussellA. E.et al (2019). Hypoxia-reoxygenation of primary astrocytes results in a redistribution of mitochondrial size and mitophagy. Mitochondrion47, 244–255. 10.1016/j.mito.2018.12.004
75
RutkaiI.MerdzoI.WunnavaS. V.CurtinG. T.KatakamP. V.BusijaD. W. (2019). Cerebrovascular function and mitochondrial bioenergetics after ischemia-reperfusion in male rats. J. Cereb. Blood Flow. Metab.39 (6), 1056–1068. 10.1177/0271678x17745028
76
RyooI. G.KwakM. K. (2018). Regulatory crosstalk between the oxidative stress-related transcription factor Nfe2l2/Nrf2 and mitochondria. Toxicol. Appl. Pharmacol.359, 24–33. 10.1016/j.taap.2018.09.014
77
SarmahD.DattaA.RautS.SarkarA.ShahB.BohraM.et al (2020). The role of inflammasomes in atherosclerosis and stroke pathogenesis. Curr. Pharm. Des.26 (34), 4234–4245. 10.2174/1381612826666200427084949
78
ShaoZ.DouS.ZhuJ.WangH.XuD.WangC.et al (2020). The role of mitophagy in ischemic stroke. Front. Neurol.11, 608610. 10.3389/fneur.2020.608610
79
ShenJ.ZhuY.HuangK.JiangH.ShiC.XiongX.et al (2016). Buyang Huanwu Decoction attenuates H2O2-induced apoptosis by inhibiting reactive oxygen species-mediated mitochondrial dysfunction pathway in human umbilical vein endothelial cells. BMC Complement. Altern. Med.16, 154. 10.1186/s12906-016-1152-7
80
ShenL.GanQ.YangY.ReisC.ZhangZ.XuS.et al (2021). Mitophagy in cerebral ischemia and ischemia/reperfusion injury. Front. Aging Neurosci.13, 687246. 10.3389/fnagi.2021.687246
81
ShiZ.ZhuL.LiT.TangX.XiangY.HanX.et al (2017). Neuroprotective mechanisms of Lycium barbarum polysaccharides against ischemic insults by regulating NR2B and NR2A containing NMDA receptor signaling pathways. Front. Cell. Neurosci.11, 288. 10.3389/fncel.2017.00288
82
SongM.ZhouY.FanX. (2022a). Mitochondrial quality and quantity control: Mitophagy is a potential therapeutic target for ischemic stroke. Mol. Neurobiol.59 (5), 3110–3123. 10.1007/s12035-022-02795-6
83
SongZ.HuangQ.GuoY.SongX.ZhangX.XiaoH. (2022b). Xingnao kaiqiao acupuncture method combined with temporal three-needle in the treatment of acute ischemic stroke: A randomized controlled trial. Comput. Intell. Neurosci.2022, 8145374. 10.1155/2022/8145374
84
SuS. H.WuY. F.WangD. P.HaiJ. (2018). Inhibition of excessive autophagy and mitophagy mediates neuroprotective effects of URB597 against chronic cerebral hypoperfusion. Cell. Death Dis.9 (7), 733. 10.1038/s41419-018-0755-y
85
SunS.JiangT.DuanN.WuM.YanC.LiY.et al (2021). Activation of CB1R-dependent PGC-1α is involved in the improved mitochondrial biogenesis induced by electroacupuncture pretreatment. Rejuvenation Res.24 (2), 104–119. 10.1089/rej.2020.2315
86
SunZ. Y.WangF. J.GuoH.ChenL.ChaiL. J.LiR. L.et al (2019). Shuxuetong injection protects cerebral microvascular endothelial cells against oxygen-glucose deprivation reperfusion. Neural Regen. Res.14 (5), 783–793. 10.4103/1673-5374.249226
87
TianW. Q.PengY. G.CuiS. Y.YaoF. Z.LiB. G. (2015). Effects of electroacupuncture of different intensities on energy metabolism of mitochondria of brain cells in rats with cerebral ischemia-reperfusion injury. Chin. J. Integr. Med.21 (8), 618–623. 10.1007/s11655-013-1512-9
88
TianW.ZhuM.ZhouY.MaoC.ZouR.CuiY.et al (2022). Electroacupuncture pretreatment alleviates cerebral ischemia-reperfusion injury by regulating mitophagy via mTOR-ULK1/FUNDC1 Axis in rats. J. Stroke Cerebrovasc. Dis.31 (1), 106202. 10.1016/j.jstrokecerebrovasdis.2021.106202
89
TingZ.JianbinZ.LuqiH. (2017). Protective effect of electroacupuncture on neurons autophagy in perfusion period of cerebral ischemia. Neurosci. Lett.661, 41–45. 10.1016/j.neulet.2017.06.043
90
ViraniS. S.AlonsoA.BenjaminE. J.BittencourtM. S.CallawayC. W.CarsonA. P.et al (2020). Heart disease and stroke statistics-2020 update: A report from the American heart association. Circulation141 (9), e139–e596. 10.1161/cir.0000000000000757
91
WangD.YuanX.LiuT.LiuL.HuY.WangZ.et al (2012). Neuroprotective activity of lavender oil on transient focal cerebral ischemia in mice. Molecules17 (8), 9803–9817. 10.3390/molecules17089803
92
WangH.ChenS.ZhangY.XuH.SunH. (2019a). Electroacupuncture ameliorates neuronal injury by Pink1/Parkin-mediated mitophagy clearance in cerebral ischemia-reperfusion. Nitric Oxide91, 23–34. 10.1016/j.niox.2019.07.004
93
WangH. Y.ZhouH. F.HeY.YuL.LiC.YangJ. H.et al (2021a). Protective effect of Naoxintong capsule combined with Guhong injection on rat brain microvascular endothelial cells during cerebral ischemia-reperfusion injury. Chin. J. Integr. Med.27 (10), 744–751. 10.1007/s11655-020-3215-3
94
WangH.ZhuJ.JiangL.ShanB.XiaoP.AiJ.et al (2020a). Mechanism of Heshouwuyin inhibiting the Cyt c/Apaf-1/Caspase-9/Caspase-3 pathway in spermatogenic cell apoptosis. BMC Complement. Med. Ther.20 (1), 180. 10.1186/s12906-020-02904-9
95
WangJ. K.GuoQ.ZhangX. W.WangL. C.LiuQ.TuP. F.et al (2020b). Aglaia odorata Lour. extract inhibit ischemic neuronal injury potentially via suppressing p53/Puma-mediated mitochondrial apoptosis pathway. J. Ethnopharmacol.248, 112336. 10.1016/j.jep.2019.112336
96
WangP.DaiL.ZhouW.MengJ.ZhangM.WuY.et al (2019b). Intermodule coupling analysis of huang-lian-jie-du decoction on stroke. Front. Pharmacol.10, 1288. 10.3389/fphar.2019.01288
97
WangP. R.WangJ. S.YangM. H.KongL. Y. (2014a). Neuroprotective effects of Huang-Lian-Jie-Du-Decoction on ischemic stroke rats revealed by (1)H NMR metabolomics approach. J. Pharm. Biomed. Anal.88, 106–116. 10.1016/j.jpba.2013.08.025
98
WangT.LiY.WangY.ZhouR.MaL.HaoY.et al (2014b). Lycium barbarum polysaccharide prevents focal cerebral ischemic injury by inhibiting neuronal apoptosis in mice. PLoS One9 (3), e90780. 10.1371/journal.pone.0090780
99
WangW.XuJ. (2020). Curcumin attenuates cerebral ischemia-reperfusion injury through regulating mitophagy and preserving mitochondrial function. Curr. Neurovasc Res.17 (2), 113–122. 10.2174/1567202617666200225122620
100
WangY.LiP.ZhangX.LiL.LiuM.LiX.et al (2021b). Mitochondrial-respiration-improving effects of three different gardeniae fructus preparations and their components. ACS Omega6 (50), 34229–34241. 10.1021/acsomega.1c03265
101
WeiW.LuM.LanX. B.LiuN.SuW. K.DushkinA. V.et al (2021). Neuroprotective effects of oxymatrine on PI3K/Akt/mTOR pathway after hypoxic-ischemic brain damage in neonatal rats. Front. Pharmacol.12, 642415. 10.3389/fphar.2021.642415
102
WuB.LuoH.ZhouX.ChengC. Y.LinL.LiuB. L.et al (2017). Succinate-induced neuronal mitochondrial fission and hexokinase II malfunction in ischemic stroke: Therapeutical effects of kaempferol. Biochim. Biophys. Acta Mol. Basis Dis.1863 (9), 2307–2318. 10.1016/j.bbadis.2017.06.011
103
WuM.LuG.LaoY. Z.ZhangH.ZhengD.ZhengZ. Q.et al (2021). Garciesculenxanthone B induces PINK1-Parkin-mediated mitophagy and prevents ischemia-reperfusion brain injury in mice. Acta Pharmacol. Sin.42 (2), 199–208. 10.1038/s41401-020-0480-9
104
XiangJ.ZhangJ.CaiX.YangF.ZhuW.ZhangW.et al (2019). Bilobalide protects astrocytes from oxygen and glucose deprivation-induced oxidative injury by upregulating manganese superoxide dismutase. Phytother. Res.33 (9), 2329–2336. 10.1002/ptr.6414
105
XieW.ZhuT.ZhouP.XuH.MengX.DingT.et al (2020). Notoginseng leaf triterpenes ameliorates OGD/R-Induced neuronal injury via SIRT1/2/3-foxo3a-MnSOD/PGC-1α signaling pathways mediated by the NAMPT-NAD pathway. Oxid. Med. Cell. Longev.2020, 7308386. 10.1155/2020/7308386
106
XuY.WangY.WangG.YeX.ZhangJ.CaoG.et al (2017). YiQiFuMai powder injection protects against ischemic stroke via inhibiting neuronal apoptosis and pkcδ/drp1-mediated excessive mitochondrial fission. Oxid. Med. Cell. Longev.2017, 1832093. 10.1155/2017/1832093
107
XueB.HuangJ.MaB.YangB.ChangD.LiuJ. (2019). Astragaloside IV protects primary cerebral cortical neurons from oxygen and glucose deprivation/reoxygenation by activating the PKA/CREB pathway. Neuroscience404, 326–337. 10.1016/j.neuroscience.2019.01.040
108
YangJ. L.MukdaS.ChenS. D. (2018). Diverse roles of mitochondria in ischemic stroke. Redox Biol.16, 263–275. 10.1016/j.redox.2018.03.002
109
YangS.ZhaoX.XuH.ChenF.XuY.LiZ.et al (2017). AKT2 blocks nucleus translocation of apoptosis-inducing factor (AIF) and endonuclease G (EndoG) while promoting caspase activation during cardiac ischemia. Int. J. Mol. Sci.18 (3), 565. 10.3390/ijms18030565
110
YangY.GaoH.LiuW.LiuX.JiangX.LiX.et al (2021). Arctium lappa L. roots ameliorates cerebral ischemia through inhibiting neuronal apoptosis and suppressing AMPK/mTOR-mediated autophagy. Phytomedicine85, 153526. 10.1016/j.phymed.2021.153526
111
YeM.WuH.LiS. (2021). Resveratrol alleviates oxygen/glucose deprivation/reoxygenation-induced neuronal damage through induction of mitophagy. Mol. Med. Rep.23 (1), 73. 10.3892/mmr.2020.11711
112
YeR.ZhangX.KongX.HanJ.YangQ.ZhangY.et al (2011). Ginsenoside Rd attenuates mitochondrial dysfunction and sequential apoptosis after transient focal ischemia. Neuroscience178, 169–180. 10.1016/j.neuroscience.2011.01.007
113
YeY.LiJ.CaoX.ChenY.YeC.ChenK. (2016). Protective effect of n-butyl alcohol extracts from Rhizoma Pinelliae Pedatisectae against cerebral ischemia-reperfusion injury in rats. J. Ethnopharmacol.188, 259–265. 10.1016/j.jep.2016.04.046
114
YinF.ZhouH.FangY.LiC.HeY.YuL.et al (2020). Astragaloside IV alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway. J. Ethnopharmacol.248, 112319. 10.1016/j.jep.2019.112319
115
ZengM.ShaoC.ZhouH.HeY.LiW.ZengJ.et al (2021a). Protocatechudehyde improves mitochondrial energy metabolism through the HIF1α/PDK1 signaling pathway to mitigate ischemic stroke-elicited internal capsule injury. J. Ethnopharmacol.277, 114232. 10.1016/j.jep.2021.114232
116
ZengM.ZhouH.HeY.WangZ.ShaoC.YinJ.et al (2021b). Danhong injection alleviates cerebral ischemia/reperfusion injury by improving intracellular energy metabolism coupling in the ischemic penumbra. Biomed. Pharmacother.140, 111771. 10.1016/j.biopha.2021.111771
117
ZhangC.WangJ.ZhuJ.ChenY.HanX. (2020a). Microcystin-leucine-arginine induced neurotoxicity by initiating mitochondrial fission in hippocampal neurons. Sci. Total Environ.703, 134702. 10.1016/j.scitotenv.2019.134702
118
ZhangF. B.WangJ. P.ZhangH. X.FanG. M.CuiX. (2019). Effect of β-patchoulene on cerebral ischemia-reperfusion injury and the TLR4/NF-κB signaling pathway. Exp. Ther. Med.17 (5), 3335–3342. 10.3892/etm.2019.7374
119
ZhangG. F.YangP.YinZ.ChenH. L.MaF. G.WangB.et al (2018a). Electroacupuncture preconditioning protects against focal cerebral ischemia/reperfusion injury via suppression of dynamin-related protein 1. Neural Regen. Res.13 (1), 86–93. 10.4103/1673-5374.224373
120
ZhangJ.LiL.ChenX.ZhangB.WangY.YamamotoK. (2000). Effects of a traditional Chinese medicine, Qing Nao Yi Zhi Fang, on glutamate excitotoxicity in rat fetal cerebral neuronal cells in primary culture. Neurosci. Lett.290 (1), 21–24. 10.1016/s0304-3940(00)01311-2
121
ZhangS.QiY.XuY.HanX.PengJ.LiuK.et al (2013). Protective effect of flavonoid-rich extract from Rosa laevigata Michx on cerebral ischemia-reperfusion injury through suppression of apoptosis and inflammation. Neurochem. Int.63 (5), 522–532. 10.1016/j.neuint.2013.08.008
122
ZhangS.ZhouY.LiR.ChenZ.FanX. (2022a). Advanced drug delivery system against ischemic stroke. J. Control Release344, 173–201. 10.1016/j.jconrel.2022.02.036
123
ZhangW.WenJ.JiangY.HuQ.WangJ.WeiS.et al (2021). l-Borneol ameliorates cerebral ischaemia by downregulating the mitochondrial calcium uniporter-induced apoptosis cascade in pMCAO rats. J. Pharm. Pharmacol.73 (2), 272–280. 10.1093/jpp/rgaa028
124
ZhangX.ZengW.ZhangY.YuQ.ZengM.GanJ.et al (2022b). Focus on the role of mitochondria in NLRP3 inflammasome activation: A prospective target for the treatment of ischemic stroke (review). Int. J. Mol. Med.49 (6), 74. 10.3892/ijmm.2022.5130
125
ZhangX.ZhangY.TangS.YuL.ZhaoY.RenQ.et al (2018b). Pien-Tze-Huang protects cerebral ischemic injury by inhibiting neuronal apoptosis in acute ischemic stroke rats. J. Ethnopharmacol.219, 117–125. 10.1016/j.jep.2018.03.018
126
ZhangY.CaoM.WuY.WangJ.ZhengJ.LiuN.et al (2020b). Improvement in mitochondrial function underlies the effects of ANNAO tablets on attenuating cerebral ischemia-reperfusion injuries. J. Ethnopharmacol.246, 112212. 10.1016/j.jep.2019.112212
127
ZhangY.YanY.CaoY.YangY.ZhaoQ.JingR.et al (2017a). Potential therapeutic and protective effect of curcumin against stroke in the male albino stroke-induced model rats. Life Sci.183, 45–49. 10.1016/j.lfs.2017.06.023
128
ZhangZ.LiuY.ZhangG.ShiF.ChenH.YinZ.et al (2017b). Effects of electroacupuncture preconditioning on activity of dynamin-related protein 1 in brain tissues during cerebral ischemia-reperfusion in rats. Chin. J. Anesthesiol.37 (12), 1498–1501. 10.3760/cma.j.issn.0254-1416.2017.12.023
129
ZhaoP.MaN. T.ChangR. Y.LiY. X.HaoY. J.YangW. L.et al (2017). Mechanism of Lycium barbarum polysaccharides on primary cultured rat hippocampal neurons. Cell. Tissue Res.369 (3), 455–465. 10.1007/s00441-017-2648-2
130
ZhaoQ.ChenA.WangX.ZhangZ.ZhaoY.HuangY.et al (2018a). Protective effects of dehydrocostuslactone on rat hippocampal slice injury induced by oxygen-glucose deprivation/reoxygenation. Int. J. Mol. Med.42 (2), 1190–1198. 10.3892/ijmm.2018.3691
131
ZhaoQ.WangX.ChenA.ChengX.ZhangG.SunJ.et al (2018b). Rhein protects against cerebral ischemic-/reperfusion-induced oxidative stress and apoptosis in rats. Int. J. Mol. Med.41 (5), 2802–2812. 10.3892/ijmm.2018.3488
132
ZhaoX. Y.WangX. Y.WeiQ. Y.XuY. M.LauA. T. Y. (2020). Potency and selectivity of SMAC/DIABLO mimetics in solid tumor therapy. Cells9 (4), 1012. 10.3390/cells9041012
133
ZhongS.LiZ.HuanL.ChenB. Y. (2009). Neurochemical mechanism of electroacupuncture: Anti-injury effect on cerebral function after focal cerebral ischemia in rats. Evid. Based Complement. Altern. Med.6 (1), 51–56. 10.1093/ecam/nem062
134
ZhongW. J.YangX. S.ZhouH.XieB. R.LiuW. W.LiY. (2022a). Role of mitophagy in the pathogenesis of stroke: From mechanism to therapy. Oxid. Med. Cell. Longev.2022, 6232902. 10.1155/2022/6232902
135
ZhongX.LiC.WangF.ChenB.LiangH.RuanS. (2022b). Mechanism of electroacupuncture at Baihui and Shenting alleviating cerebral ischemia-reperfusion injury via regulating BNIP3L-mediated mitophagy. Rehabil. Med.32 (01), 32–39. 10.3724/sp.j.1329.2022.01006
136
ZhouH.HeY.ZhuJ.LinX.ChenJ.ShaoC.et al (2021a). Guhong injection protects against apoptosis in cerebral ischemia by maintaining cerebral microvasculature and mitochondrial integrity through the PI3K/AKT pathway. Front. Pharmacol.12, 650983. 10.3389/fphar.2021.650983
137
ZhouK.ChenJ.WuJ.WuQ.JiaC.XuY. X. Z.et al (2019). Atractylenolide III ameliorates cerebral ischemic injury and neuroinflammation associated with inhibiting JAK2/STAT3/Drp1-dependent mitochondrial fission in microglia. Phytomedicine59, 152922. 10.1016/j.phymed.2019.152922
138
ZhouX.ChenH.WangL.LenahanC.LianL.OuY.et al (2021b). Mitochondrial dynamics: A potential therapeutic target for ischemic stroke. Front. Aging Neurosci.13, 721428. 10.3389/fnagi.2021.721428
139
ZhouX.WangH. Y.WuB.ChengC. Y.XiaoW.WangZ. Z.et al (2017). Ginkgolide K attenuates neuronal injury after ischemic stroke by inhibiting mitochondrial fission and GSK-3β-dependent increases in mitochondrial membrane permeability. Oncotarget8 (27), 44682–44693. 10.18632/oncotarget.17967
140
ZhouZ. W.RenX.ZhengL. J.LiA. P.ZhouW. S. (2022). LncRNA NEAT1 ameliorate ischemic stroke via promoting Mfn2 expression through binding to Nova and activates Sirt3. Metab. Brain Dis.37 (3), 653–664. 10.1007/s11011-021-00895-1
141
ZhouZ. Y.TangY. P.XiangJ.WuaP.JinH. M.WangZ.et al (2010). Neuroprotective effects of water-soluble Ganoderma lucidum polysaccharides on cerebral ischemic injury in rats. J. Ethnopharmacol.131 (1), 154–164. 10.1016/j.jep.2010.06.023
142
ZhuT.FangB. Y.MengX. B.ZhangS. X.WangH.GaoG.et al (2022). Folium Ginkgo extract and tetramethylpyrazine sodium chloride injection (Xingxiong injection) protects against focal cerebral ischaemia/reperfusion injury via activating the Akt/Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Pharm. Biol.60 (1), 195–205. 10.1080/13880209.2021.2014895
143
ZhuT.XieW. J.WangL.JinX. B.MengX. B.SunG. B.et al (2021). Notoginsenoside R1 activates the NAMPT-NAD(+)-SIRT1 cascade to promote postischemic angiogenesis by modulating Notch signaling. Biomed. Pharmacother.140, 111693. 10.1016/j.biopha.2021.111693
Summary
Keywords
traditional Chinese medicine, mitochondria, molecular mechanism, review, ischemic stroke
Citation
Liu L, Chen D, Zhou Z, Yuan J, Chen Y, Sun M, Zhou M, Liu Y, Sun S, Chen J and Zhao L (2023) Traditional Chinese medicine in treating ischemic stroke by modulating mitochondria: A comprehensive overview of experimental studies. Front. Pharmacol. 14:1138128. doi: 10.3389/fphar.2023.1138128
Received
05 January 2023
Accepted
10 March 2023
Published
22 March 2023
Volume
14 - 2023
Edited by
Yusof Kamisah, Faculty of Medicine Universiti Kebangaan Malaysia, Malaysia
Updates
Copyright
© 2023 Liu, Chen, Zhou, Yuan, Chen, Sun, Zhou, Liu, Sun, Chen and Zhao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ling Zhao, zhaoling@cdutcm.edu.cn; Jiao Chen, chenjiao@cdutcm.edu.cn
† These authors have contributed equally to this work
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.